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The role of extracellular heat shock proteins in posttraumatic stress 
disorder-related inflammation  
 
Abstract 
Post-traumatic stress disorder (PTSD) is a debilitating psychiatric disorder that may 
develop following exposure to life-threatening traumatic event. PTSD represents a serious 
medical and economic burden for the society due to its relatively high life-time prevalence 
rate and comorbidity with variety of other mental disorders and somatic illnesses. General 
opinion is that the best results in understanding of PTSD pathogenesis, diagnosis and 
treatment could be achieved by integrating psychological, biological and 
pharmacotherapeutical approaches. 
Current research has suggested that PTSD is associated with neuroendocrinological 
disturbances and immune function alterations. The hypersensitivity of hypothalamic-pitui-
tary-adrenocortical (HPA) axis to cortisol feedback inhibition is considered the 
neuroendocrine hallmark of PTSD, while the nature of PTSD-related immune alterations is 
not well understood. Most studies report that PTSD is associated with excessive 
inflammation, but unaltered inflammatory state and even decreased circulatory levels of 
inflammatory markers were also reported. It has been hypothesized that excessive 
inflammation in individuals with PTSD might be a consequence of insufficient 
immunosuppression by cortisol. However, the data on cortisol levels and cortisol receptor 
functioning in PTSD patients are inconsistent.  
Exposure to a variety of stressors will induce intracellular heat shock proteins (HSPs) 
with cellular functions beneficial for cell survival. For many years HSPs have been viewed 
as intracellular proteins, but it is now known that they can be released from various 
mammalian cells into the peripheral circulation, where they are capable of activating 
pro-inflammatory responses. Taking that PTSD-associated excessive inflammation is not 
likely to be caused by impaired anti-inflammatory action of cortisol, we hypothesize that it 





The aim of the present study was to relate the parameters of inflammatory status 
with circulatory levels of HSPs and cortisol, and to uncover possible associations between 
inflammatory markers and extracellular HSPs with trauma-exposure, PTSD symptoms, 
vulnerability and resilience to PTSD. Toward that end the relevant parameters were 
determined in patients with current PTSD (N=118) and life-time PTSD (N=63), in 
trauma-exposed individuals without PTSD (N=94) and in non-traumatized healthy subjects 
(N=95). The measured parameters were: circulatory levels of a number of cytokines and 
C-reactive protein, as inflammatory markers; intracellular levels of HSPs (Hsp90, Hsp70, 
Hsp72 and Hsp60); plasma levels of HSPs (Hsp70, Hsp72 and Hsp60); plasma level of 
cortisol before and after suppression of HPA axis by dexamethasone and the level of 
corticosteroid receptors, glucocorticoid receptor (GR) and mineralocorticoid (MR), in 
peripheral blood mononuclear cells (PBMCs). 
Plasma levels of pro-inflammatory cytokines, markers of inflammation and 
extracellular HSPs (eHsp60 and eHsp70) were determined by ELISA, while 
semi-quantitative Western blot was performed for determination of lymphocyte level of 
corticosteroid receptors and HSPs. 
The results demonstrate that the alterations in plasma levels of cortisol, Hsp70s and 
Hsp60, as well as the MR level and MR/GR balance in peripheral lymphocytes are not 
associated with trauma exposure, current or life-time PTSD symptoms, resilience to PTSD, 
vulnerability to PTSD and/or with remission of the disorder. However, vulnerability to 
PTSD is characterized by hypersensitivity of HPA axis to cortisol and by increased level of 
GR expression in PBMCs. The levels of expression of HSPs (Hsp90, Hsp70, Hsp72 and 
Hsp60) in the lymphocytes do not vary between current PTSD, life-time PTSD, trauma 
control and healthy control groups of subjects. Interestingly, MR level in peripheral 
lymphocytes is correlated with the levels of both Hsp90 and Hsp70, while the GR level is 
correlated only with that of Hsp90. The strength of correlation between the lymphocyte 
levels of MR and Hsp70 is related to current PTSD, while war trauma-exposure may 
improve correlation between the levels of GR and Hsp90. Judging by the levels of general 
inflammatory markers (CRP, erythrocytes sedimentation rate, leukocyte count) and 
cytokines (TNF-α, IL-6, IL-12p70, IL-2, IL-8, IFN-γ, IL-5, IL-4, IL-10), trauma-exposure and 




levels of some cytokines (TNF-α, IL-6, IL-12p70, IL-2 and IL-8) might be connected with 
trauma-exposure rather than with the presence of current or life-time PTSD symptoms, 
while the levels of others (IFN-γ, IL-5, IL-4 and IL-10) could be related to vulnerability to 
PTSD rather than to trauma-exposure. 
The results of the present PhD project constitute an original scientific contribution to 
better understanding of the molecular mechanisms underlying pathophysiology of PTSD. 
Specifically, they add to unraveling the relationship between inflammation and trauma or 
vulnerability/resilience to PTSD, and shed a new light on the role of extracellular HSPs in 
PTSD-related inflammatory actions of the immune system. 
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Uloga vanćelijskih proteina toplotnog stresa u inflamaciji povezanoj sa 
posttraumatskim stresnim poremećajem 
 
Rezime 
Posttraumatski stresni poremećaj (PTSP) je psihijatrijska bolest koja se može razviti 
posle izlaganja traumatskom događaju. PTSP predstavlja veliko medicinsko i ekonomsko 
opterećenje za društvo, zbog relativno velike učestalosti i komorbiditeta sa mnogim drugim 
psihijatrijskim i somatskim bolestima. Smatra se da se najbolji rezultati u razumevanju 
patogeneze PTSP-a i njegovoj dijagnostici i terapiji mogu postići integrisanjem psiholoških, 
bioloških i farmakoterapeutskih pristupa. 
Aktuelna istraživanja sugerišu da je PTSP povezan sa neuroendokrinim 
poremećajima i promenama imunskih funkcija. Smatra se da je hiperosetljivost 
hipotalamo-hipofizno-adrenokortikalne (HHA) ose na kortizol neuroendokrini „pečat“ 
PTSP-a, dok je priroda imunskih poremećaja povezanih sa PTSP-om još uvek nejasna. 
Većina studija pokazala je da je PTSP povezan sa pojačanom inflamacijom, ali su objavljeni i 
podaci o nepromenjenom inflamatornom statusu, pa čak i smanjenom nivou inflamatornih 
markera u cirkulaciji PTSP pacijenata. Pretpostavlja se da pojačana inflamacija kod osoba 
obolelih od PTSP-a može biti posledica nedovoljne imunosupresije kortizolom. Međutim, 
podaci o nivou kortizola i funkcionisanju kortizolskih receptora kod pacijenata sa PTSP-om 
nisu konzistentni. 
Izlaganje različitim stresorima indukuje sintezu unutarćelijskih proteina toplotnog 
stresa (HSP) čije funkcije potpomažu preživljavanje ćelija. Tokom mnogo godina HSP su 
posmatrani kao unutarćelijski proteini, ali sada se zna da ih mnoge sisarske ćelije 
oslobađaju u cirkulaciju, gde mogu da aktiviraju pro-inflamatorne odgovore. Uzimajući da 
pojačana inflamacija koja je povezana sa PTSP-om verovatno nije posledica umanjenog 
anti-inflamatornog delovanja kortizola, mi smo pretpostavili da ona može biti posledica 
indukcije i oslobađanja Hsp60 i Hsp70 psihološkom traumom. 
Cilj ove studije bio je da se povežu parametri inflamatornog statusa sa nivoima 
kortizola i HSP u cirkulaciji, kao i da se otkriju moguće veze između inflamatornih markera 




PTSP. U tom cilju u studiju su bili uključeni pacijenia sa aktuelnim PTSP-om (N=118), osobe 
koje su prebolele PTSP (N=63), osobe izložene traumi koje nisu razvile PTSP (N=94) i 
zdrave, netraumatizovane kontrole (N=95). Izmereni parametri bili su: unutarćelijski nivoi 
HSP (Hsp90, Hsp70, Hsp72 i Hsp60), nivoi HSP (Hsp70, Hsp72 i Hsp60) u krvnoj plazmi, 
nivo kortizola u plazmi pre i posle supresije HHA ose deksametazonom i nivoi 
kortikosteroidnih receptora, glukokortikoidnog receptora (GR) i mineralokortikoidnog 
receptora (MR), u perifernim limfocitima. 
Nivoi proinflamatornih citokina, markera inflamacije i vanćelijskih HSP (eHsp60 i 
eHsp70) u krvnoj plazmi određivani su metodom ELISA, dok je semi-kvantitativni 
„Western blot“ korišćen za određivanje nivoa kortikosteroidnih receptora i HSP u 
limfocitima. 
Rezultati su pokazali da se promene nivoa kortizola, Hsp70 i Hsp60 u plazmi, kao i 
nivo MR i ravnoteža između MR i GR u limfocitima ne mogu povezati sa izlaganjem traumi, 
aktuelnim ili prebolovanim PTSP-om, osetljivošću i otpornošću na PTSP, niti sa oporavkom 
od PTSP-a. Međutim, osetljivost na PTSP karakteriše se hiperosetljivošću HHA ose na 
kortizol i povećanim nivoom ekspresije GR-a u perifernim limfocitima. Nivo ekspresije HSP 
(Hsp90, Hsp70, Hsp72 i Hsp60) u limfocitima ne razlikuje se između osoba sa aktuelnim 
PTSP-om, prebolovanim PTSP-om, traumatizovanih osoba bez PTSP-s i zdravih, 
netraumatizovanih kontrola. Interesantno je da postoji korelacija nivoa MR-a sa nivoima 
Hsp90 i Hsp70 u limfocitima, dok nivo GR-a koreliše samo sa nivoom Hsp90. Jačina 
korelacije između nivoa MR i Hsp70 u limfocitima može se povezati sa aktuelnim 
simptomima PTSP-a, dok izlaganje traumi pojačava korelaciju između nivoa GR-a i Hsp90. 
Sudeći prema opštim inflamatornim markerima (CRP, sedimentacija eritrocita, broj 
leukocita) i nivoima citokina (TNF-α, IL-6, IL-12p70, IL-2, IL-8, IFN-γ, IL-5, IL-4, IL-10), 
izlaganje traumi i PTSP se mogu povezati sa imunosupresijom, pre nego sa pojačanom 
inflamacijom.  Nivoi nekih citokina (TNF-α, IL-6, IL-12p70, IL-2, IL-8) mogli bi se povezati 
sa izlaganjem traumi, pre nego sa prisustvom aktuelnih ili prošlih simptoma PTSP-a, dok se 
nivoi drugih citokina (IFN-γ, IL-5, IL-4, IL-10) mogu povezati sa osetljivošću na PTSP, pre 
nego sa izlaganjem traumi. 
Rezultati ovog doktorskog projekta predstavljaju originalan naučni doprinos boljem 




Posebno, oni doprinose razotkrivanju veze između inflamacije i traume, odnosno 
osetljivosti/otpornosti na PTSP, i rasvetljavanju uloge vanćelijskih HSP u inflamatornim 
funkcijama imunskog sistema povezanim sa PTSP-om. 
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ACTH – adrenocorticotropic hormone 
AHA1 – Hsp90 co-chaperone  
ANCOVA – analysis of covariance 
ANOVA – one-way analysis of variance  
AP-1 – activating protein-1 
BDI-II – Beck’s Depression Inventory II 
BSA – bovine serum albumine 
CAPS-DX – Clinician Administered PTSD Scale 
CBP – cyclic AMP-responsive element-binding protein 
CD14 – TLR co-receptor for bacterial lipopolysaccharide 
CD40 – receptor on the surface of antigen presenting cells 
CD91 – receptor for Grp96 
CDC37 – Hsp90 co-chaperone 
CRH – corticotrophin-releasing hormone 
CRP – C-reactive protein 
Cyp40 – cyclosporin A-binding immunophilin 
DEX – dexamethasone 
DSM-IV – Diagnostic and Statistical Manual of Mental Disorders-IV 
DST – dexamethasone suppression test 
eHsp60 – extracellular Hsp60 
eHsp70 – extracellular Hsp70 
eHSPs – extracellular HSPs 
ELISA – enzyme-linked immunosorbent  assay 
FKBP51/52 – FK506-binding protein 51/52 
GR – glucocorticoid receptor 
GRE – glucocorticoid-responsive element 
GroEL/GroES complex – prokaryotic homolog of mitochondrial Hsp60 chaperone 
system 
Grp96 – 96 kDa glucose-regulated protein 
HAT – histone acetyltransferase 




HDL – high density lipoproteins 
HIP – Hsp70-interacting protein 
HOMA – Homeostasis Model Assessment  
HOP – Hsp70/Hsp90 organizing protein 
HPA axis – hypothalamic-pituitary-adrenocortical axis  
HRP – horse-radish peroxidase 
HSBP1 – heat shock protein binding factor 1 
HSE – heat shock element 
HSF – heat shock factor 
Hsp100 – 100kDa heat shock protein family 
Hsp40 – 40kDa heat shock protein family 
Hsp60 – 60kDa heat shock protein family 
Hsp70 – 70kDa heat shock protein family 
Hsp90 – 90kDa heat shock protein family 
HSPs – heat shock proteins 
ICAM-1 – intracellular adhesion molecule 
IFN-γ – interferon γ  
IL-10 – interleukin-10 
IL-12p70 – interleukin-12p70 
IL-1β – interleukin-1 beta( 
IL-2 – interleukin-2 
IL-4 – interleukin-4 
IL-6 – interleukin-6 
IL-8 – interleukin-8 
KD – equilibrium dissociation constant 
LDL – low density lipoproteins 
MR – mineralocorticoid receptor 
NFκB – nuclear factor κB  
nGREs – negative GREs 
p23 – Hsp90 co-chaperone 
PBMCs – peripheral blood mononuclear cells 
PBS – phosphate buffered saline 
POMC – proopiomelanocortin  




SAM system – sympathetic-adrenal medullary system 
SCID-I – Structured Clinical Interview for DSM Disorders 
SD – standard deviation 
SDS-PAGE – SDS-polyacrylamide gels electrophoresis 
sHSPs – small heat shock proteins 
SPSS – Statistical Programme for Social Sciences 
SUMO – small ubiquitine-like modifier 
TLRs – Toll-like receptors 
TNFα – tumor necrosis factor alpha 
TRIC (or CCT) – cytoplasmic form of eukaryotic Hsp60  
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1.1 Posttraumatic stress disorder 
Since the Vietnam War, posttraumatic stress disorder (PTSD) has become 
one of the most discussed psychiatric conditions in the United States. The recent 
spates of natural disasters worldwide have brought PTSD to the forefront again. 
Trauma is an integral part of human existence, but only recently have the 
biological and psychological aspects of exposure to different traumatic conditions 
been scientifically studied. By definition, PTSD is a debilitating psychiatric disorder 
that may develop following exposure to life threatening traumatic event. The 
traumatic event that may lead to development of PTSD symptoms is defined as 
experiencing, witnessing or being confronted with one or several events that 
involve actual or threatened death or serious injury or threat to the physical 
integrity of self or others (Blake et al., 1996). The person exposed to such a 
traumatic event responds with intense fear, helplessness, or horror. As a 
consequence of trauma-exposure, PTSD symptoms may emerge immediately or be 
delayed in the months after the exposure. The major PTSD symptoms include re-
experiencing of the trauma (intrusions), avoidance of trauma-related stimuli, 
emotional numbing and hyperarousal, and they significantly impair the person’s 
social, occupational and other important areas of functioning (criteria B to F).  
PTSD is frequently comorbid not only with a wide variety of mental 
disorders, primarily major depression, but also with physical illness, particularly 
cardiovascular disease (Boscarino, 2004; Schnurr & Green, 2004). These data, 
together with relatively high life-time prevalence rates, show that PTSD represents 




1.1.1 Current definition of PTSD 
PTSD may develop in individuals who experience horror, helplessness, and 
fear after threat or death. In addition, it is represented by presence of three 
unequivocal, but co-occurring, symptom clusters: 1) Individuals must have been 
exposed to a traumatic event; 2) The event involved a perceived or actual threat to 
the person’s own life or physical integrity, or witnessing the threat to life or 
physical integrity of another person, such as a physical or sexual assault, rape, a 
serious accident, a natural disaster, combat, being taken hostage, torture, 
displacement as a refugee, sudden unexpected death of a loved one, and witnessing 
a traumatic event; 3) The traumatic memory can be insuppressible in the form of 
nightmares or images which are chaperoned by violent physiological agony. The 
reminders of the event-related revocation symptoms include impose restrictions 
on thoughts and distancing, as well as more generalized emotional and social 
withdrawal. PTSD can be defined clearly when an individual was exposed to a 
traumatic event and this is required for diagnosis of PTSD, making PTSD a 
psychiatric disorder which by definition is related to and occurs as a consequence 
of a stressful or traumatic event.  
1.1.2 Prevalence of posttraumatic stress disorder 
Nearly 50-70% of the U.S.A. population is exposed to traumatic event some 
times during the lifetime. In a nationally representative study of 5877 people aged 
15-45 in the U.S.A. (Kessler et al., 1995), a lifetime prevalence of exposure to 
trauma was found to be 60.7% in men and 51.2% in women, while the prevalence 
of PTSD is about 5% in men and 10% in women. In the U.S.A., the National 
women`s study (NWS) (Resnick et al., 1993) found that 69.0% of women were 
exposed to a traumatic event sometimes in their lives. In 2005, an estimated 162 
million of people worldwide were affected by disasters. Earthquakes illustrate the 
burden of natural disasters. Worldwide, there are over 20000 earthquakes and 
over 1300 per year with magnitude 5 or greater (National Earthquakes 




Exposure to a variety of stressors that most often give rise to PTSD include 
assault, combat and rape, whereas natural disasters or man-made accidents result 
in PTSD far less frequently. Disaster workers, who combat with fires, earthquakes, 
hurricanes, plane crashes and other disasters, are at high risk of PTSD as well 
(Fullerton et al., 2004; Benedek et al., 2007). In addition, across the world most of 
soldiers deployed to fight and civilians in modern cities face the large number of 
traumatic stressors, including terrorism, rape, war, assault, accidents, childhood 
abuse and other acute psychological traumas. 
1.1.3 Symptoms of posttraumatic stress disorder 
The symptoms of PTSD include intrusive thoughts (e.g. nightmares, 
unwanted thoughts), hyperarousal, such as startle responses or physiological 
arousal, avoidance of reminders of traumatic event and numbing of emotional 
responses. Avoidance symptoms involve restricting thoughts and distancing 
oneself from reminders of the event, as well as more generalized emotional and 
social withdrawal. Hyperarousal symptoms explain more overt physiological 
manifestations, for example impaired concentration, hypervigilance, insomnia, 
irritability, and increased distaste responses. The diagnosis of PTSD can be put 
forward one month after exposure to a traumatic event if the symptoms last at 
least one month and are severe enough to weaken social skills or interpersonal 
functioning. Vulnerability to PTSD is enhanced by poor coping strategies, 
substance abuse, co-occurring mood and anxiety disorders, lack of social support, 
and the accelerated development of stress related medical conditions (Yehuda, 
2002b). Actually, the expected response to traumatic events is resilience. However, 
minority of trauma-exposed men and women suffer the psychological stress of the 
trauma exposure and develop distress, psychiatric illness, and exhibit health risk 
behaviors. Indeed, concern for future, increased fear and arousal, and altered sense 
of safety after exposure to trauma, can affect not only those who develop mental 
health problems, but also those who keep on working and care for their families 




1.1.4 Comorbid disorders 
PTSD is frequently comorbid with major depression and a wide variety of 
other mental disorders, and also with physical illness. Chronic sympathetic 
activation in PTSD may have important implications for the individual risk to 
develop cardiovascular disease as well as other chronic medical illnesses. Indeed, 
patients with PTSD have increased rates of comorbidity with cardiovascular 
diseases and other chronic somatic conditions (Boscarino, 2004; Boscarino, 2008; 
Kibler, 2009). Recently Heppner and colleagues reported that PTSD severity 
predicted the presence of metabolic syndrome (Heppner et al., 2009). However, 
PTSD does not appear to be associated with diabetes mellitus (Qureshi et al., 2009) 
or increased waist-to-hip ratio (Heppner et al., 2009). This suggests that PTSD may 
enhance the risk for insulin resistance, especially in the context of obesity. PTSD 
has also been linked to rheumatoid arthritis (Qureshi et al., 2009), independent of 
genetic and familial factors (Boscarino et al., 2010). Other chronic medical 
conditions that have been associated with PTSD include psoriasis and thyroid 
disease (Boscarino, 2004). Interestingly, each of these chronic somatic disorders 
has inflammatory or autoimmune underpinnings. It is therefore reasonable to 
suspect that patients with PTSD may display immune alterations in addition to 
neuroendocrine changes. 
1.1.5 Vulnerability and resilience to and recovery from PTSD 
The findings that only a minority of trauma-exposed individuals develop or, 
even more importantly, maintain PTSD led to a hypothesis that PTSD involves a 
failure of mechanisms involved in recovery and restitution of physiological 
homeostasis. These findings have also prompted an interest in identifying 
vulnerability (risk) factors for this disorder. It has been supposed that individual 
variations in biological phenotypes of PTSD originate from pretraumatic 
vulnerability factors. Further research revealed that PTSD vulnerability factors 
include event characteristics (e.g., severity of trauma) and individual differences 




shown that prevalence of PTSD is greater after exposure to interpersonal violence 
than after accidents, raising the possibility that distinct biological subtypes of PTSD 
are based on trauma type. However, the line delineating stressor severity based on 
objective characteristics of the traumatic event versus the subjective response of 
the victim has never been clear. The risk factors for PTSD also include a family 
history of psychopathology, cognitive factors (such as low intelligence quotient), 
childhood adversity, preexisting avoidant personality or behavioral problems, and 
poor social support (Yehuda et al., 2007). 
It has been clear for a long time that response of different individuals to the 
same traumatic event is not uniform (Yehuda & LeDoux, 2007). A multitude of 
responses to adversity has raised an interest not only in vulnerability (risk) 
factors, but also in resilience factors. Resilience may be a mediator that may 
explain why psychopathology does not always develop. If biomarkers of resilience 
could be identified, these could be used to either predict (if they are trait-related 
i.e. genetically determined) or track (if they are state-related i.e. reflect adaptability 
to stress) recovery from traumatic events. Identifying true correlates of resilience 
could certainly provide important insights into the mechanisms promoting 
resilience or recovery from traumatic stress. Moreover, if resilience is an enduring 
characteristic or trait that is identifiable even before trauma exposure, it could be 
used to predict responses to adversity in those who may be at high risk for 
occupational or other hazards (Yehuda & Flory, 2007). 
Up to date little is known about the biological basis of individual differences 
in response to trauma and specific questions regarding associations among risk 
and resilience factors, trauma exposure, development of psychopathology and 
recovery from the disorder still remain to be answered. To that end, choosing an 
appropriate research design that can lead to distinguishing factors associated with 
risk, symptom severity, recovery, and stress resistance is of an utmost importance. 
Prospective studies examining psychological aspects of vulnerability, resilience 
and recovery over time, may provide information on biological features that can 
predict outcome in response to adversity. In cross-sectional studies, it is important 




putative resilience-related measures are preexisting traits that are unaffected by 
trauma exposure, these would presumptively be measurable in at least some 
nonexposed persons, perhaps making exposed and nonexposed groups 
indistinguishable on this measure. Conversely, if resilience markers reflect trauma 
exposure, because they are correlated with exposure or activated by exposure, 
group differences may not be discernible if a nonexposed group is excluded from 
the study. These factors suggest that cross-sectional studies should include 
nonexposed and exposed individuals, although only a prospective, longitudinal 
approach can evaluate the impact of trauma exposure, as well as assess resilience-
related factors, since they may develop and change over time (Yehuda & Flory, 
2007). 
An interesting question is whether resilience is the opposite of vulnerability, 
or in other words, whether psychopathology will occur in the absence of resilience. 
The approach to answering this question should include differentiating trauma-
exposed persons on the basis of presence or absence of (current and/or lifetime) 
PTSD, and then making a second distinction based on the presence or absence of a 
known risk factor for PTSD. This strategy can distinguish between measures 
reflecting resilience, risk, and psychopathology. It is also very important to 
distinguish between resistance to PTSD and recovery from this condition. Toward 
that end, special attention should be paid on how participants are classified, and 
how the group comparisons are made. 
1.2 Neuroendocrine alterations in PTSD  
The symptoms of PTSD are believed to reflect stress-induced changes in 
neurobiological systems and/or an inadequate adaptation of neurobiological 
systems to exposure to severe stressors. Over the last three decades, biological 
research on PTSD has focused on two major hormone systems that form the 
backbone of the physiological response to stress: the hypothalamic-pituitary-adre-
nocortical (HPA) axis and the sympathetic-adrenal-medullary (SAM) system. Focus 




to a traumatic event and that glucocorticoids and catecholamines are ”stress 
hormones” that may regulate responses to trauma. In the 1990’s, it became clear 
that PTSD is not a normative response to extreme stressors, as only a subset of 
people exposed to trauma will develop the disorder. Yehuda therefore 
reconceptualized PTSD as a disorder of stress response systems, leading to 
maladaptive responses and a failure to cope with the stressor (Yehuda, 2009). A 
search of the literature reveals multiple papers documenting changes of the HPA 
axis and the SAM system in PTSD patients. 
1.2.1 Hypothalamic-pituitary-adrenocortical (HPA) axis 
The HPA axis is activated when an organism is confronted with challenge and 
it acts to re-establish the homeostasis of the body. Therefore, the HPA axis 
functions as a feedback loop, which results in a cascade of associated processes to 
down-regulate the bodily responses to stress. The HPA axis is a complex set of 
interactions between the hypothalamus, the pituitary gland and the adrenal glands. 
The primary structure of the central nervous system involved in the regulation of 
HPA axis is the paraventricular nucleus of the hypothalamus. The paraventricular 
nucleus is the principal source of the corticotrophin-releasing hormone (CRH), 
which is the major physiological regulator of pituitary adrenocorticotropic 
hormone (ACTH) secretion. The CRH hypophysiotropic neurons from the 
paraventricular nucleus project to the external zone of the median eminence and 
release CRH into a specialized capillary network. Within the anterior pituitary, 
CRH interacts with a specific G protein-coupled receptor on the corticotrope cell 
surface, resulting in the stimulation of the synthesis of the ACTH precursor peptide 
proopiomelanocortin (POMC) and the secretion of ACTH and other POMC-derived 
peptides. ACTH potently induces the secretion of glucocorticoids from the zona 
fasciculata of the adrenal cortex. In a classical endocrine feedback manner, these 
steroids inhibit the synthesis and secretion of CRH within the hypothalamus and 




HPA axis function is frequently investigated by measuring changes in cortisol, 
ACTH, or CRH release. The dexamethasone suppression test (DST) is a sensitive 
clinical measure of the functional integrity of the negative feedback mechanism 
mediated by glucocorticoid receptor (GR): the cortisol-suppressing activity of the 
synthetic glucocorticoid, DEX, is an indicator of GR status (Carroll et al., 1981). A 
newer test is the combined dexamethasone/CRH (DEX/CRH) challenge test, in 
which the HPA axis is both stimulated by the administration of CRH and inhibited 
with dexamethasone. This test is said to be more sensitive for detecting HPA axis 
abnormalities in patients with psychiatric disorders (Heuser et al., 1994). 
Figure 1.1 – The hypothalamic-pituitary-adrenocortical (HPA) axis. The HPA axis 
functions as a feedback loop. The paraventricular nucleus of the hypothalamus is the 
principal source of the corticotrophin-releasing factor, which is the major 
physiological regulator of pituitary adrenocorticotropic hormone secretion. 
Adrenocorticotropin potently induces the secretion of cortisol from the zona 
fasciculata of the adrenal cortex. In a classical endocrine feedback manner, cortisol 
inhibits the synthesis and secretion of corticotrophin-releasing factor within the 
hypothalamus and adrenocorticotropin in the pituitary (modified from Yehuda, R., N. 
Engl. J. Med., 2002, 346:108-114). 
1.2.2 Corticosteroid receptors 
Activation of the HPA system results in secretion of glucocorticoids. In 




corticosterone is the main steroid product of the zona fasciculata. Corticosteroids 
(cortisol and aldosterone) exert their actions through specific intracellular 
receptors, mineralocorticoid (or Type I) and glucocorticoid (or Type II) receptors 
(MR and GR, respectively). More recently, evidence has been presented for the 
existence of cell surface steroid receptors, and second messengers inside cells that 
may result in steroid-induced non-genomic actions (Christ et al., 1999). 
Historically, glucocorticoids were thought to bind exclusively to GR and 
aldosterone to MR, and regulate carbohydrate and sodium homeostasis 
respectively. However, following in vitro observations that both receptors bind to 
glucocorticoids with high affinity, they were classified as Type 1 „high affinity” 
receptor (corresponding to the MR) and Type 2 „low affinity” receptor 
(corresponding to GR). Separate receptors for glucocorticoids and 
mineralocorticoids appear to have occurred via gene duplication late in evolution, 
explaining why they behave in a similar fashion in some circumstances. The MR is 
classified as „high affinity” since it binds cortisol with a high affinity (Kd ~ 1nM) 
(Arriza et al., 1987). The GR binds cortisol with equilibrium dissociation constant 
(KD) between 20 and 40 nM and therefore is classified as „low affinity” receptor 
(Reul & de Kloet, 1985). The MR is expressed in target tissues such as epithelia of 
renal distal tubules, salivary glands and distal colon, as well as within the central 
nervous system, in the placenta and fetal tissues, and in bone cells. The GR is 
widely expressed in tissues involved in glucose homeostasis, such as liver, adipose 
tissue and muscle, as well as bone cells and cells in the immune system. 
Cytosolic GR is found in its target cells in the form of multiprotein 
heterocomplexes the components of which are molecular chaperones (Hsp90 and 
Hsp70), co-chaperones, immunophilins (FKBP51/52) and some other proteins. 
Steroid binding to the cytosolic GR results in the activation of the receptor 
complex, involving the dissociation of Hsp90 and Hsp70 (Hutchison et al., 1993). 
Nuclear localization signal on the receptor is masked by chaperone proteins, but 
are exposed upon hormone binding and chaperone dissociation. The two 
unmasked receptor’s nuclear localization signals allow protein interaction with the 




been translocated to the nucleus, there is stimulation or repression of gene 
transcription by its binding to glucocorticoid response elements (GRE) in the 
promoter regions of target genes (Beato et al., 1996). 
The similar mechanism of activation and transcriptional activation/repre-
ssion is characteristic for MR (or Type I receptor). However, its regulation and 
properties are still a matter of investigation. The high affinity MR is substantially 
occupied even at basal levels of HPA axis activity, suggesting that this receptor is 
implicated in the maintenance of basal activity of the stress system by proactive 
feedback. High concentrations of corticosteroids progressively saturate GR, 
implying that the suppression of stress-induced HPA activity occurs, in particular, 
through GR by reactive feedback in a coordinated manner with MRs. Consequently, 
the balance between MR- and GR-mediated actions on the stress system is of 
critical importance to the set point of HPA activity and proper response to stress. 
1.2.3 HPA axis alterations in PTSD 
While cerebrospinal fluid levels of CRH are increased in patients with PTSD 
(Bremner et al., 1997), the data on peripheral cortisol concentrations are 
inconsistent. Many studies have found that peripheral concentrations of cortisol 
are decreased (Rohleder et al., 2004), whereas other studies found no differences 
between PTSD patients and controls (Young & Breslau, 2004), or even higher 
cortisol levels in PTSD (Lemieux & Coe, 1995). 
With respect to HPA axis function, several studies suggest that PTSD patients 
exhibit enhanced glucocorticoid sensitivity. In studies using DST with a low dose of 
dexamethasone, a potent synthetic glucocorticoid with five times higher affinity for 
the GR, HPA axis functioning was suppressed and enhanced negative feedback 
inhibition was observed in PTSD patients as compared to controls, reflecting in 
hypersuppression of cortisol secretion in blood or saliva (Kosten et al., 1990; 
Griffin et al., 2005). Yehuda and colleagues were the first to demonstrate that 
patients with PTSD showed enhanced sensitivity to glucocorticoids during the DST, 




1.2). This “sensitization” of the HPA axis is in line with the main PTSD symptoms 
like an unusually heightened response to stress, hypervigilance and especially 
physiological hyperarousal (Boscarino & Chang, 1999; Yehuda, 2001; Wessa et al., 
2006). However, later studies using the DST have found little or no differences 
between PTSD patients and trauma exposed controls without PTSD (Wessa & 
Rohleder, 2007). Thus, it is somewhat unclear if PTSD patients consistently display 
enhanced glucocorticoid sensitivity during the DST. Heim and colleagues found 
lower cortisol levels during the DEX–CRH test in men with abuse-related PTSD, 
which is consistent with the idea of enhanced feedback suppression under 
conditions of additional challenge (Heim et al., 2008). 
Figure 1.2 – Response to stress in a normal subject, a patient with major 
depressive disorder and a patient with PTSD. In normal subjects (panel A) and in 
patients with major depression (panel B) brief or sustained periods of stress are 
typically associated with increased levels of both cortisol and corticotrophin-releasing 
factor. In each panel the thickness of the interconnecting arrows denotes the 
magnitude of the biological response. Corticotrophin-releasing factor stimulates the 
production of corticotrophin, which in turn stimulates the production of cortisol. 
Cortisol inhibits the release of corticotrophin from the pituitary and the release of 
corticotrophin-releasing factor from the hypothalamus. It is also responsible for the 
containment of many biological reactions. In patients with PTSD (panel C), levels of 
cortisol are low and levels of corticotrophin-releasing factor are high. In addition, the 
sensitivity of the negative feedback system of the HPA axis is increased in patients 
with PTSD, rather than decreased, as often occurs in patients with major depression 




Glucocorticoid sensitivity can also be measured in circulating immune cells. 
Several original reports suggest that circulating immune cells from patients with 
PTSD may be more sensitive to glucocorticoids compared to immune cells from 
healthy individuals (Wolf et al., 2009; Rohleder et al., 2010). For example, 
lysozyme activity has been found to be more sensitive to dexamethasone in bulk 
leukocytes collected from PTSD patients compared to cells obtained from healthy 
controls. In addition, lipopolysaccharide-induced cytokine production from whole 
blood, a measure of monocyte responsiveness, has been reported to be more 
sensitive to dexamethasone in samples collected from PTSD patients compared to 
samples from controls (Wolf et al., 2009; Rohleder et al., 2010). However, not all 
findings point to enhanced glucocorticoid sensitivity in immune tissues from PTSD 
patients. De Kloet and colleagues compared the sensitivity of various immune 
parameters to dexamethasone in cell samples from patients with PTSD, trauma 
exposed controls, and controls not exposed to trauma (de Kloet et al., 2007). While 
they found that the sensitivity of lipopolysaccharide-induced cytokine production 
to dexamethasone did not vary as a function of PTSD or trauma exposure, the 
sensitivity of phytohemagglutinin-induced T cell proliferation to dexamethasone 
was actually reduced in samples collected from PTSD patients versus those 
obtained from controls with or without trauma exposure (de Kloet et al., 2007). 
The disagreement between measures of glucocorticoid sensitivity when using 
lipopolysaccharide-induced cytokines as an endpoint may be explained by 
differences in assay protocols or control conditions (de Kloet et al., 2007). The 
finding of decreased sensitivity of T cell proliferation to glucocorticoids may not 
necessarily conflict with studies using lipopolysaccharide-induced cytokines or 
lysozyme activity endpoints, as each explores different aspects of immune 
function. In other words, there is the intriguing possibility that PTSD involves 
decreased glucocorticoid sensitivity in some immune tissues and increased 
glucocorticoid sensitivity in others.  
There is also a lack of clarity with respect to changes of GR density in immune 
cells as a correlate of PTSD. Several studies investigated the number of GR on 




They demonstrated that GR number correlated with the severity of combat-related 
PTSD symptoms while no relationship with plasma cortisol levels could be 
observed (Yehuda et al., 1991). In addition, higher lymphocyte counts in PTSD 
patients were found as well as positive correlations of total lymphocyte GR 
expression with the number of years after trauma (PTSD patients) and with serum 
cortisol concentration (Vidovic et al., 2007). While a number of studies have 
reported increased expression of GR in circulating immune cells, other reports 
suggest that GR density may actually be decreased (Gill et al., 2009). As with 
measures of glucocorticoid sensitivity, this disagreement in GR expression in 
patients with PTSD could involve clinical differences between studies regarding 
patient groups. Methodological difference could also be important, including 
different techniques to assess GR density or expression levels, as well as 
assessments of these parameters in different subpopulations of immune cells. 
Collectively, the findings of the summarized prospective studies indicate that 
individuals vulnerable to PTSD have deregulations on various levels of the 
glucocorticoid signaling cascade (Figure 1.3): low levels of circulating cortisol 
shortly after trauma (McFarlane et al.; Delahanty et al., 2000; Aardal-Eriksson et 
al., 2001; Ehring et al., 2008), high GR number in peripheral blood mononuclear 
cells (PBMCs) (van Zuiden et al., 2011a; van Zuiden et al., 2012), high GILZ mRNA 
expression and low FKBP5 expression in PBMCs prior to trauma (van Zuiden et al., 
2012), and high sensitivity of immune cells for regulation by glucocorticoids prior 
to trauma (van Zuiden et al., 2012). In addition, single nucleotide polymorphisms 
in the GR and fkbp5 genes have been found to be associated with PTSD (Binder et 
al., 2008; Xie et al., 2010; Boscarino et al., 2011; Hauer et al., 2011; Boscarino et al., 
2012) and the non-genetic vulnerability factors for PTSD (van Zuiden et al., 
2011b). The results of these studies tentatively suggest that the development of 





Figure 1.3 – Overview of currently identified vulnerability factors for PTSD in 
the glucocorticoid signaling pathway. Solid arrows between the vulnerability 
factors and PTSD indicate that presence/high levels of the vulnerability factors are 
associated with the development of PTSD. Striped arrows indicate that absence/low 
levels of the vulnerability factors are associated with development of PTSD. For the 
single nucleotide polymorphisms, the allele associated with increased risk for PTSD is 
presented. Abbreviations: GC: glucocorticoid; DEX: dexamethasone; PBMCs: 
peripheral blood mononuclear cells; GR: glucocorticoid receptor; SNPs: single 
nucleotide polymorphisms (reproduced from van Zuiden, M. et al., Biol. Psychiatry, 
2012, 71:309-316). 
1.2.4 SAM system alterations in PTSD 
A cardinal feature of patients with PTSD is sustained hyperactivity of the 
sympathetic branch of autonomic nervous system, as evidenced by heart rate, 
blood pressure, skin conductance level, and other physiological measures. 
Moreover, central and peripheral concentrations of noradrenaline appear to be 
elevated in patients with PTSD. One study reported increased CSF concentrations 
of noradrenaline in veterans with the disorder (Geracioti et al., 2001). Decreased 
platelet α2 receptor binding further suggests noradrenaline hyperactivity in PTSD 
(Vermetten & Bremner, 2002; Strawn & Geracioti, 2008). Accordingly, increased 
urinary excretion of noradrenaline and adrenaline, and their metabolites, has been 
documented in combat veterans, abused women, and children with PTSD. There is 
also evidence for a role of altered central noradrenaline function in PTSD. 
Administration of the α2 receptor antagonist yohimbine, which increases NE 




patients with PTSD (Southwick et al., 1999). Serial sampling revealed sustained 
increases in noradrenaline concentrations in cerebrospinal fluid and increased 
noradrenaline responses to psychological stressors in PTSD (Geracioti et al., 2001; 
Geracioti et al., 2008). Taken together, increased noradrenaline reactivity plausibly 
contributes to features of PTSD, including hyperarousal, increased startle, and 
encoded fear memories (Strawn & Geracioti, 2008). Some studies have found 
increased urine noradrenaline levels in PTSD patients exposed to various types of 
trauma including domestic abuse, childhood abuse, combat, automobile accidents, 
and exposure to war as a refugee (reviewed in Wessa & Rohleder, 2007). Urinary 
adrenaline concentrations are also increased in patients with PTSD (Wessa & 
Rohleder, 2007). Only one study has attempted to measure noradrenaline levels in 
blood (Yehuda et al., 1998). Beyond catecholamines, studies investigating 
cardiovascular variables in PTSD patients support the notion of increased SAM 
reactivity. Thus, patients with PTSD exhibit increased heart rate, blood pressure, 
and tremor responses when presented with reminders of traumatic events (Bedi & 
Arora, 2007). The 5-HT system interacts with the CRH and noradrenaline systems 
in coordinating affective and stress responses (Ressler & Nemeroff, 2000; 
Vermetten & Bremner, 2002). Indirect evidence suggests a role of 5-
hydroxytryptamine in the pathophysiology of PTSD, including symptoms of 
impulsivity, hostility, aggression, depression, and suicidality. Most important role 
of 5-hydroxytryptamine circuits in PTSD is the demonstrated efficacy of the 
selective serotonin reuptake inhibitors. Other evidence for altered 
5-hydroxytryptamine neurotransmission in PTSD includes decreased serum 
concentrations of 5- hydroxytryptamine, decreased density of platelet 
5-hydroxytryptamine uptake sites, and altered responsiveness to central 
serotonergic challenge (Ressler & Nemeroff, 2000; Vermetten & Bremner, 2002). 
However, no differences in 5- hydroxytryptamine 1A receptor binding were 
detected in patients with PTSD compared to controls using positron emission 




1.2.5 Is neuroendocrine deregulation a risk factor for the 
development of PTSD? 
While most studies conceptualized neuroendocrine changes as correlates of 
the disease state of PTSD, several studies now suggest that neuroendocrine 
deregulation may in fact be a risk factor that predicts the development of the 
disorder upon exposure to extreme stress. Some studies have evaluated whether 
altered neuroendocrine responses observed in the immediate outcome of a trauma 
predict PTSD. Indeed, SAM and HPA axis responses to traumatic events have been 
shown to predict later development of PTSD. According to Yehuda’s model, PTSD 
develops because key aspects of the biological response to trauma interfere with 
recovery after the trauma (Yehuda, 2009). Indeed, low plasma concentrations of 
cortisol and elevated plasma catecholamines in the period of time immediately 
after trauma have been found to predict PTSD development (Yehuda, 2009). If 
cortisol responses to trauma normally facilitate suppression of catecholamine 
responses to the same event, then reduced cortisol following a trauma may 
promote an excessive catecholamine response. This enhanced sympathetic activity 
may amplify encoding of traumatic memories, which would encourage expression 
of key PTSD features (Yehuda, 2009). These results raised the intriguing possibility 
that neuroendocrine deregulation may be a pre-existing risk factor that is present 
well before and independent of the traumatic event that elicits PTSD. Several 
prospective studies have now assessed neuroendocrine changes prior to trauma 
exposure. Indeed, increased glucocorticoid binding in peripheral blood 
mononuclear cells before deployment has been found to predict the development 
of PTSD 6 months after deployment in army personnel (van Zuiden et al., 2009). In 
addition, exaggerated startle responses in police academy cadets, measured 
prospectively, have also been found to predict the development of PTSD (Pole et 
al., 2009). This suggests that healthy people who show enhanced startle responses 
are at increased risk for developing PTSD. Risk for PTSD may also be transmitted 
across generations. Lower plasma concentrations of cortisol have been found in 




at DST), and in babies from mothers who developed PTSD after the World Trade 
Center attack in New York City (Yehuda, 2009).  
1.3 PTSD and immunity/inflammation 
1.3.1 Central and peripheral inflammatory markers 
In 1997, Spivak and colleagues were the first to measure plasma cytokine 
levels in PTSD patients. They discovered that, compared to healthy, non-trauma 
exposed controls, veterans with PTSD displayed increased circulating 
concentrations of interleukin-1 beta (IL-1β) that were also correlated with the 
duration of PTSD symptoms (Spivak et al., 1997). This finding has been bolstered 
by subsequent studies. Higher tumor necrosis factor alpha (TNFα) was found in 
PTSD patients with mixed trauma experience versus non-PTSD controls (von Kanel 
et al., 2007). In addition, higher plasma IL-6 levels and soluble interleukin-6 (IL-6) 
receptors were found in victims of an automobile accident or a hotel fire compared 
to healthy controls (Maes et al., 1999). Higher IL-6 levels have also been reported 
in patients with PTSD subsequent to myocardial infarction as compared to patients 
with myocardial infarction who did not develop PTSD, when controlling for 
depressive symptoms (von Kanel et al., 2010). Refugees with PTSD following 
hurricane Katrina exhibited higher circulating IL-6 concentrations compared to 
refugees without PTSD (Tucker et al., 2010). Moreover, the analysis of serum IL-2, 
IL-4, IL-6, IL-8, IL-10 and TNF-α level in PTSD patients has revealed significantly 
elevated peripheral cytokine levels for all cytokines compared to age- and gender-
matched healthy controls (Guo et al., 2012). Alterations in inflammatory markers 
are evident not just in the peripheral circulation, but in the central nervous system 
as well. Hence, elevated IL-6 concentrations have been measured in cerebrospinal 
fluid of PTSD patients with combat trauma exposure compared to healthy controls 
(Baker et al., 2001). Given that IL-6 is thought to drive C-reactive protein (CRP) 
production from the liver, several recent studies have also examined CRP levels in 




nearly two-fold higher chance of having elevated CRP levels, even after controlling 
for possible confounds including sex, age, and alcohol use (Spitzer et al., 2010). 
Despite multiple reports of increased circulating and central nervous system 
cytokines in PTSD patients, two studies have found decreased inflammatory 
markers. Most recently, von Känel and colleagues found lower CRP in patients with 
PTSD (von Kanel et al., 2007). Lower CRP was also found in Iraqi refugees with 
PTSD (Sondergaard et al., 2004). The lack of agreement between these studies may 
involve unique participant characteristics. For example, Sondergaard and 
colleagues noted that control participants in their study may have infections more 
likely than PTSD patients (Sondergaard et al., 2004), leading to higher circulating 
CRP concentrations in the control group. Results from studies on patients with 
myocardial infarction should be interpreted carefully as well, given the 
complicated medical status of these individuals. Finally, a recent report suggests 
that trauma exposure and PTSD may instill epigenetic changes that impact long-
term inflammatory function (Uddin et al., 2010). In this study, patients with PTSD 
were found to exhibit a greater number of unmethylated genes related to innate 
immune and inflammatory function compared to healthy controls, which could 
eventually encourage the expression of altered immune function and enhanced 
inflammatory activity. 
1.3.2 Neuroendocrine–immune interactions in PTSD 
Neuroendocrine studies suggest that PTSD is not exclusively dependent on 
exposure to trauma. Instead, the onset and course of the disorder may involve a 
number of biological variables including altered cortisol levels, enhanced 
glucocorticoid sensitivity, altered GR numbers on immune cells, altered startle 
responses, and increased SAM system activity. Thus, atypical interactions between 
immune and neuroendocrine systems may help to explain the inflammatory excess 
found in a portion of patients with PTSD. Because glucocorticoids are well known 
for their anti-inflammatory effects, it is reasonable to theorize that reduced 
circulating concentrations of cortisol seen in some patients with PTSD may be 




unaware of studies directly relating cortisol and inflammatory markers in PTSD, 
attenuated cortisol responses have been associated with enhanced IL-6 and IL-1β 
responses to stress in healthy individuals (Kunz-Ebrecht et al., 2003). This 
suggests that low circulating concentrations of cortisol may foster a 
hyperinflammatory state, especially in the context of stress. However, the actions 
of hormones are not determined solely as a function of circulating concentrations. 
Instead, hormone effects also depend on tissue sensitivity, which is determined by 
receptor density and receptor function. As discussed above, PTSD patients have 
been found to exhibit altered glucocorticoid sensitivity in endocrine tissues and 
immune cells. In addition, many studies suggest that GR number may be increased 
in immune cells. Assuming that patients with PTSD exhibit enhanced 
glucocorticoid sensitivity and higher GR number, we can propose that patients 
with the disorder should have ‘‘normal” concentrations of circulating inflammatory 
markers despite low plasma cortisol level (Pace & Heim). One may even predict 
that patients with PTSD would have reduced inflammatory markers. Yet, most of 
the studies suggest that PTSD involves enhanced inflammatory activation.  
1.3.3 From PTSD to medical comorbidities via immune 
dysfunction 
As discussed in Section 2.1.4, PTSD is often comorbid with a number of 
chronic medical illnesses that have immune underpinnings. Could inflammatory 
and autoimmune changes that appear with the onset of PTSD encourage later 
development of the same comorbid medical illnesses? Although short-lived 
inflammation may be beneficial for combating pathogen exposure or tissue 
damage, chronic inflammation is well known to increase the risk for chronic 
medical illnesses. In this section, we will briefly illustrate a 
psycho-neuroimmunological model of PTSD, by focusing on two disease states that 





Connections between PTSD, immune function and cardiovascular disease 
may begin with increased concentrations of proinflammatory cytokines in the 
circulation that appear with the onset of PTSD. Circulating cytokine changes can 
persist for months, and perhaps years, along with ongoing PTSD symptoms. 
Although prospective studies are yet to demonstrate that the onset of PTSD 
symptoms is associated with increased circulating inflammatory markers, as noted 
above, increased plasma levels of IL-6 at the time of trauma have been associated 
with later development of PTSD (Pervanidou et al., 2007). In addition, acute and 
chronic stressors are well known to increase inflammatory markers (Segerstrom & 
Miller, 2004). Of note, PTSD has already been prospectively associated with the 
development of heart disease 15 years later in veterans who were free of heart 
disease at baseline (Boscarino, 2008). Along with increased lipoproteins, 
inflammation within the wall of blood vessels fosters the atherosclerotic process 
(Sprague & Khalil, 2009). Increased circulating concentrations of proinflammatory 
cytokine associated with PTSD may eventually activate inflammatory signaling 
pathways (e.g. NFκB) in vascular cells of vessel wall. Inflammatory pathway 
activation in these cells encourages increased cell adhesion, increased vessel 
permeability, and apoptosis. Monocytes are then able to attach more readily to 
vessel walls, and eventually mature into macrophages. These macrophages then 
amplify the proinflammatory message in the vascular wall by secreting additional 
IL-1β and TNF-α, as well as other factors, which further increase expression of 
adhesion molecules, such as vascular cell adhesion molecule-1. Macrophages 
eventually become large foam cells, forming “fatty streaks” inside vessels that can 
develop into atherosclerotic lesions. Proinflammatory cytokines would also draw 
smooth muscle cells to the lesion, forming fibrous capsules over these lesions. 
Finally, circulating proinflammatory cytokines have been shown to potentiate 
thrombosis, or rupture of atherosclerotic lesions, leading to myocardial infarction 
or ischemic stroke (Tousoulis et al., 2006). Although cardiovascular disease 
depends on a number of factors, including dietary habits, smoking, and exercise, it 
is conceivable that increased inflammation begun by trauma and PTSD may 




Inflammation has also been implicated in the pathophysiology of insulin 
resistance and metabolic syndrome. Multiple studies have found that chronic 
activation of inflammatory signaling pathways can lead to obesity-related insulin 
resistance. In the psycho-neuroimmunological model of PTSD, elevated circulating 
concentrations of proinflammatory cytokines associated with PTSD would 
potentiate activation of macrophages in adipose tissue and the liver, the tissues 
that are central to insulin resistance. These activated macrophages are the main 
generators of inflammatory products, such as TNF-α, that go on to induce 
inflammatory signaling pathways within insulin target cells. Increased 
inflammatory signaling activity within insulin target cells is then able to antagonize 
normal insulin receptor signaling (Olefsky & Glass, 2010). Although increased 
inflammation as a result of trauma and PTSD may not be sufficient to induce 
insulin resistance alone, the model predicts that inflammatory changes induced by 
PTSD would synergize with other factors, including visceral adiposity and exercise 
habits, to encourage development of insulin resistance and metabolic syndrome. 
Although work to date supports an immune component in mechanisms linking 
PTSD and chronic medical illness, more information is needed. Prospective studies 
will need to demonstrate that immune changes subsequent to trauma and the 
onset of PTSD can predict disease development.  
1.4 Heat Shock Proteins (HSPs)  
The first evidence for a cellular stress response is generally associated with a 
set of experiments in fruit flies (Ritossa, 1962). Larvae of Drosophila melanogaster 
were accidentally kept overnight at an elevated temperature and upon inspection 
the next day, an unusual puffing pattern was noticed on salivary gland 
chromosomes, indicating that the “heat shock” episode had caused marked 
changes in the gene expression pattern of the larvae. However, the term “heat 
shock protein” was not coined until 1974, when specific protein products 
associated with these genes were identified in fruit flies (Tissieres et al., 1974). 




response, has been extensively studied, particularly with regard to stress proteins 
and their ever expanding array of functions (Lindquist & Craig, 1988; Hightower, 
1991; Welch, 1992). Cellular stress response represents adaptive response which 
helps to maintain cellular homeostasis under stress and is based on 
macromolecular damage recognition without regard to the type of stress that 
causes such damage. Elevated expression of heat shock proteins (HSPs), also 
named stress proteins, is sufficient to protect cells from various cytotoxic agents, 
while at the same time downregulation of most other genes, responsible for 
“normal” cellular functions was noticed (Prahlad & Morimoto, 2009). The 
molecular meshanisms underlying cellular stress response are conserved from 
archaebacteria to mammals. 
Up to date HSPs are classified on the basis of their apparent molecular 
masses into the following main distinct families: Hsp100, Hsp90, Hsp70, Hsp60, 
Hsp40 and small HSPs (sHsp). Some members of these Hsp families are present 
constitutively in cells, while some are expressed only after stress. Each family is 
comprised of multiple members that share sequence similarity and have common 
main functional domains, such as ATP-binding domain, substrate-binding domain 
and cofactor-binding domain. Most of HSPs are molecular chaperones, typically 
bound to nonnative conformation of proteins that are accumulated in the cells 
exposed to stressors. These interactions protect proteins from aggregation and 
enable refolding and the restoration of their biological active conformations (Hartl 
et al., 1994; Morano & Thiele, 1999; Bukau et al., 2006). Molecular chaperones 
have extremely conserved sequences, some of them sharing 50% homology 
between mammals and bacteria (Henderson & Henderson, 2009). However, it has 
become very apparent over the past two decades that molecular chaperones have 
additional functions besides their protein refolding actions. Namely, HSPs have a 
dual function depending on their intracellular or extracellular location. In the cell, 
these proteins play an essential role as molecular chaperones by assisting the 
correct folding of nascent and refolding of stress-accumulated misfolded proteins, 
prevent their aggregation, or promote degradation of irreparably damaged 




mediate immunological responses. These proteins in contact with immune cells 
can elicit an immune response modulated either by the adaptive or innate immune 
system (Schmitt et al., 2007). Therefore, HSPs have moonlighting functions and the 
nature of these functions depends on where these proteins exist in the organism. 
The most important function of molecular chaperones in homeostasis is to 
prevent protein aggregation during the synthesis by trapping the hydrophobic 
surfaces of nascent polypeptide chains and to facilitating correct folding. If the 
functions of chaperons are decreased, misfolded proteins accumulate and 
aggregation rises in the cell. Thus, molecular chaperones are essential for 
protecting cells against the toxicity of misfolded proteins and theirs aggregates 
(Kubota, 2009).  
On the other hand, the role of HSPs is inevitable in the response to variety of 
stressors, including extremes of temperature, cellular energy depletion, and 
extreme concentrations of ions, other osmolytes, gases, and various toxic 
substances (Feder & Hofmann, 1999). All known stressors, if sufficiently intense, 
induce HSPs expression. Accordingly, HSPs are equally well termed stress proteins, 
and their expression is termed the stress response. A common aspect of these 
stresses is that they result in intracellular accumulation of proteins having non-
native conformations and HSPs assist partially denaturated proteins in restoring 
their native states.  
1.4.1 Hsp70 chaperone system 
Molecular chaperones form functional complexes with other molecules of the 
same or another chaperone group, or with co-chaperones and cofactors. These 
multiprotein complexes represent chaperone mashines, which usually involve 
more than one chaperoning team (Macario & Conway de Macario, 2007). In several 
cases chaperones interact with a specific target protein, named substrate or client, 
and become obligatory for its folding, as well as for its assembly with other 
proteins in specific protein complexes. These specific interactions make 




network, the signaling network, the membranous and organellar network, as well 
as the transcriptional network. One of the most important molecules in the entire 
protein folding network is Hsp70. The prokaryotic version, called DnaK, shares 
about 60% sequence identity with eukaryotic Hsp70 proteins, which are found in 
the cytosol and in organelles, such as the endoplasmic reticulum, mitochondria, 
and chloroplasts. Under physiological conditions, Hsp70s are involved in de novo 
folding of newly formed proteins, in uncoating of clathrin coated vesicles, in 
reorganization of cytoskeleton systems, translation initiation, transport of proteins 
through membranes, nuclear protein import and export, ribosome assembly, 
protection of nucleolar structure and in protein degradation (Nover & Scharf, 
1997). Under stress they prevent the aggregation of misfolded proteins and can 
even refold them (Mayer & Bukau, 2005). The basic function of Hsp70 in all cases 
is evidently binding and subsequent release of partially unfolded proteins in an 
ATP-dependent cycle. 
Members of the Hsp70 family consist of a single polypeptide with two 
functional domains, an ATPase domain and a protein binding domain. The N-
terminal domain is able to bind and hydrolyze ATP, whereas the C-terminal 
protein-binding domain contains four hydrophobic pockets for binding unfolded 
target proteins. After binding of ATP, Hsp70 is able to interact with non-native 
proteins characterized by exposition of hydrophobic peptide motifs at their 
surface. Subsequent ATP hydrolysis generates an Hsp70-ADP complex with tightly 
bound substrate proteins. After ADP—ATP exchange, the target polypeptide is 
released to undergo folding in solution (Figure 1.4). 
The activity of Hsp70s is regulated by cochaperones. The largest class of 
Hsp70 cochaperones is the group of Hsp40/J-domain-containing proteins 
(Kampinga & Craig). They bind the nonnative protein and deliver it to Hsp70. The J 
domains of these proteins interact with the ATPase domain of Hsp70 and stimulate 
the hydrolysis of bound ATP. The release of nucleotide and substrate is further 





Figure 1.4 – The Hsp90 chaperone cycle. Hsp70 is switched between high- and low-
affinity states for unfolded and partially folded protein by ATP binding and hydrolysis. 
Unfolded and partially folded substrate (nascent chain or stress-denatured protein), 
exposing hydrophobic peptide segments, is delivered to ATP-bound Hsp70 (open, low 
affinity conformation) by one of several Hsp40 cofactors. The hydrolysis of ATP, which 
is accelerated by Hsp40, results in closing of the α-helical lid of the peptide-binding 
domain (yellow) and tight binding of substrate by Hsp70 (closed, high affinity 
conformation). Dissociation of ADP catalyzed by one of several nucleotide-exchange 
factors (NEFs) is required for recycling. Opening of the α-helical lid, induced by ATP 
binding, results in substrate release (reproduced from Hartl, U.F. et al., Nature, 2011, 
475:324-332). 
1.4.2  Hsp60 chaperone system  
Eukaryotes possess Hsp60s both in the cytoplasm and in the organelles, 
mitochondria and chloroplasts. Cytoplasmic forms are designated TRIC or CCT and 
are responsible, in cooperation with Hsp70, for de novo folding of nascent 
polypeptides and refolding of misfolded proteins. Mitochondrial and chloroplast 
Hsp60 chaperonin is typically held responsible for folding of nascent proteins and 
refolding of misfolded proteins in the mitochondrial matrix. The homolog of 
mitochondrial Hsp60 chaperone system is the E. coli GroEL/GroES complex 
(Hayer-Hartl et al., 1996) that was structurally analyzed by Hartl (Hartl, 1996; 
Hayer-Hartl et al., 1996; Hunt et al., 1996) and Xu et al. (Xu et al., 1997). Under 
normal physiological conditions, Hsp60/GroEL is a 60 kDa oligomer composed of 
monomers that form a complex arranged as two stacked heptameric rings. This 
double ring structure forms a large central cavity in which the unfolded protein 
binds via hydrophobic interactions. Each Hsp60/GroEL monomer consist of three 
different domains: (i) an apical domain interacting with the cochaperone 




and the apical domain together and is required for ATP hydrolysis and (iii) an 
equatorial domain interacting with the second ring and harboring an ATP binding 
side. The apical domains expose a set of hydrophobic amino acid residues towards 
the inner surface of the cavity thus offering binding sites for partially unfolded 
proteins. Target proteins bound to the hydrophobic surfaces may therefore 
undergo further mechanical unfolding. The unfolded substrates remain 
encapsulated, protected from unwanted interactions and free to spontaneously 
fold into the native conformations, for the time needed for ATP hydrolysis. Once 
the ATP is hydrolyzed, the co-chaperone dissociates and folded/refolded substrate 
protein is released (Figure 1.5). 
 
Figure 1.5 – Reaction cycle of the GroEL-GroES chaperonine system. Substrate 
protein is transferred to GroEL from Hsp70. ATP binding then triggers a 
conformational rearrangement of the GroEL apical domains. This is followed by the 
binding of GroES and substrate encapsulation for folding. The enclosed substrate 
protein experiences confinement in the cavity, as well as shielding from the crowded 
environment of the bacterial cytosol. At the same time, ADP and GroES dissociate from 
the opposite (trans) GroEL ring, allowing the release of substrate that had been 
enclosed in the former cis complex (omitted from the figure for simplicity). The new 
substrate remains encapsulated, free to fold, for the time needed to hydrolyze the 
seven ATP molecules in the newly formed cis complex (~10 s). Binding of ATP and 
GroES to the trans ring causes the opening of the cis complex (reproduced from Hartl, 
U.F. et al., Nature, 2011, 475:324-332). 
Hsp60 are amongst the most evolutionary conserved proteins. The significant 
functional, structural, and sequential homology between Hsp60 and its prokaryotic 




responsible for maintaining the integrity of cellular proteins, particularly in 
response to environmental stresses such as temperature, concentration imbalance, 
pH change, and toxins. Hsp60 aids in the folding and conformation maintenance of 
approximately 15-30% of all cellular proteins. 
1.4.3 Hsp90 chaperone system 
Hsp90 belongs to the most abundant constitutively expressed cytosolic 
chaperones in eukaryotic cells (Hendrick & Hartl, 1993; Jakob & Buchner, 1994; 
Buchner, 1996; Nemoto & Sato, 1998). Its  prokaryotic analogue is HtpG (high-
temperature protein G), which share  40% sequence identity with the human 
protein (Chen et al., 2006). The cytosolic protein in vertebrates exists in two 
isoforms (α and β) which demonstrate 85% sequence homology. The α- and β-
forms are thought to be the result of a gene duplication event that occurred 
millions of years ago. Hsp90 functions as a dimer of subunits that are assembled by 
their C-terminal domains. An N-terminal domain binds and hydrolyses ATP and is 
joined to the C-terminal domain by a middle domain (Figure 1.6). The middle 
domain participates in substrate binding and interacts with co-chaperones. Similar 
to other chaperones, the Hsp90 dimer undergoes an ATP-driven reaction cycle that 
is accompanied by considerable structural rearrangement. ATP binding leads to 
the dimerization of the N-terminal domains, forming the Hsp90 ‘molecular clamp’. 
This results in a compaction of the Hsp90 dimer, in which the individual 
monomers twist around each other. After hydrolysis, the ATPase domains 
dissociate, and the Hsp90 monomers separate N-terminally  (Figure 1.6). Various 
cofactors regulate this cycle: CDC37, which delivers certain kinase substrates to 
Hsp90, inhibits the ATPase activity, and HOP inhibits N-terminal dimerization. 
AHA1 stimulates ATP hydrolysis, whereas p23 stabilizes the dimerized form of 
Hsp90 before ATP hydrolysis. These factors are thought to adjust the kinetic 
properties of the cycle to achieve certain conformational transitions in Hsp90-





Figure 1.6 – Hsp90 chaperone cycle. Clockwise from top left, ATP binding to the N-
terminal ATPase domain (ND) of apo-Hsp90 induces a conformational change and the 
closure of the ATP lid in the ND. After lid closure, the NDs dimerize, forming the closed 
Hsp90 dimer (molecular clamp) with twisted subunits. This metastable conformation 
is committed for ATP hydrolysis. After hydrolysis, the NDs dissociate. The inactive 
substrate molecule interacts mostly with the middle domain (MD) and is 
conformationally activated as Hsp90 proceeds through the ATPase cycle. The 
cofactors CDC37, HOP, AHA1 and p23 accelerate or slow certain steps of the cycle 
(reproduced from Hartl, U.F. et al., Nature, 2011, 475:324-332). 
Hsp90 is reported to play an important role in signal transduction pathways, 
since its clients include most of the signaling proteins. For example, it has been 
demonstrated that Hsp90 participates in maturation and activation of Ser/Thr- 
and Tyr-specific protein kinases (Cutforth & Rubin, 1994; Dey et al., 1996; Nair et 
al., 1996; Schulte et al., 1996; Stepanova et al., 1996; Chang et al., 1997; Nair et al., 
1997). The other well-known role of Hsp90 is chaperoning of steroid hormone 
receptors, including the GR and MR. Unliganded steroid receptors exist in cytosols 
in heterooligomeric complexes with Hsp90 and Hsp70 (Pratt & Toft, 1997b). The 
interaction between the Hsp70 and Hsp90 chaperone systems is mediated by 
cochaperones HOP (Hsp70/Hsp90 Organizing Protein) (Johnson et al., 1998) and 
Hip (Hsp70-interacting protein) (Smith et al., 1993; Johnson et al., 1998). In 
addition, Hsp90 complex interacts with three other proteins, FKBP52, Cyp40 and a 
small acidic protein, p23. These proteins also act as co-chaperones that increase 
the overall efficiency of GR-Hsp90 heterocomplex assembly. The role of Hsp70 is to  
recognize newly synthesized receptors, and it is required for their initial folding, 




conformation and maintains unliganded receptors in transcriptionally inactive 
state by keeping them in a form incapable of DNA binding. Hsp90 also controls 
intracellular trafficking, nuclear retention, transcriptional activity (Grad & Picard, 
2007), as well as proteolytic degradation of the receptors (Siriani et al., 2005). 
Final receptor activation and translocation to the nucleus is achieved upon 
dissociation of the hormone-receptor complex from Hsp90. Therefore, the 
interaction of steroid hormone receptors with Hsp90 and Hsp70 represents an 
important determinant of target tissue sensitivity to these hormones (Pratt & Toft, 
1997a; Grad & Picard, 2007). 
1.4.4 Induction and regulation of heat shock protein expression 
Transcriptional regulation of Hsp genes is mediated by the interaction of heat 
shock factor (HSF) with heat shock elements (HSE) located in the promoter 
regions of Hsp genes (Voellmy, 1994; Srivastava, 2002). In vertebrates, four HSFs 
have been identified, of which HSF1 and HSF2 are ubiquitously expressed and 
conserved (Hightower & Guidon, 1989; Theriault et al., 2005). The main heat shock 
factor, participating in the  response of vertebrates to physiological and 
environmental stress, is HSF1 (Guzhova et al., 2001). The activity of HSF2 is more 
selective, and is mostly induced during differentiation and early development 
(Pockley et al., 2003) Usually, HSF1 is present in the cytoplasm as a latent 
monomeric molecule in a complex with Hsp70 or Hsp90 and their cofactors, in 
which it is unable to bind to DNA. When the cell is exposed to stress, the 
accumulation of non-native proteins leads to HSF1 activation (Morimoto et al., 
1994), by sequestration of Hsp70 and release of HSF1 from the complexes with 
chaperones. HSF1 is then converted to trimeric form that have a capacity to 
translocate from the cytoplasm to the nucleus (Figure 1.7). In the nucleus, it 
becomes hyperphosphorylated in a Ras-dependent manner by mitogen-actived 
protein kinases (Knauf et al., 1996; Kim et al., 1997) and sumoylated, acquiring the 
ability to bind to DNA. The induction of HSPs has to be tightly controlled, since 
their presence would adversely affect protein homeostasis and intracellular 




the cell returns to normal function, the level of misfolded proteins decline and the 
free chaperones, now present in excess, capture HSF1 again, leading to cessation  
of Hsp genes expression (Shi et al., 1998). A second mechanism regulating HSPs 
synthesis is the interaction between heat shock protein binding factor 1 (HSBP1), 
the active trimeric form of HSF1 and Hsp70, resulting in inhibition of the capacity 
of HSF1 to bind to DNA (Satyal et al., 1998). HSBP1 is mainly localized in the 
nucleus, and HSBP1 mRNA is present at high concentrations in various cell lines 
and animal tissues that are unaffected by heat chock. 
Figure 1.7 – Regulation of the Heat Shock Response. In eukaryotes, a storage form 
of the heat shock specific transcription factor HSF1 is maintained in an inactive 
monomeric form in complexes with the chaperones Hsp70 and Hsp90. As in the case 
of the prokaryotic system, the titration of chaperones by massive protein unfolding 
upon proteotoxic stress will result in the release of HSF1 from chaperone inactivation. 
Monomeric HSF1 then trimerizes, is transported into the nucleus, 
hyperphosphorylated, sumoylated, and activates heat shock gene transcription 




1.5 Extracellular HSPs 
To date, extracellular HSPs (eHSPs), have mainly been studied in the context 
of intracellular chaperones, and their release from cells has typically been believed 
to occur only after lysis. Now it is known that HSPs can be secreted from a variety 
of cell types, even when cells are completely viable. Release of such proteins from 
cells is triggered by physical trauma and psychological stress, as well as by 
exposure to immunological "danger signals". Extracellular stress protein release 
occurs through both physiological secretion mechanisms and cell death by 
necrosis. After release into the extracellular fluid, HSPs may bind to the surfaces of 
adjacent cells and initiate signal transduction cascades, as well as the transport of 
cargo molecules such as antigenic peptides. In addition, some HSPs are able to 
enter the bloodstream and may possess the ability to act at distant sites in the 
body (Calderwood et al., 2007). It is now known that these proteins can be 
released from a variety of viable (non-necrotic) mammalian cells including 
neuronal cells, monocytes, macrophages, B cells, tumor cells of epithelial origin, 
endothelial cells and hepatosplanchnic tissue (Child et al., 1995; Bassan et al., 
1998; Liao et al., 2000; Febbraio et al., 2002). The release of HSPs into circulation 
was found to be connected to behavioral stress or trauma, extreme exercise 
(Pockley, 2002; Campisi & Fleshner, 2003) and physical or psychological acute 
stressors (Fleshner & Johnson, 2005). However, some of these proteins (e.g. Hsp60 
and Hsp70) were found to be present also in the peripheral circulation of normal 
individuals (Pockley et al., 1998; Pockley et al., 1999), with, as yet, unclear impact 
on pathophysiological processes. 
1.5.1 Immune and inflammatory effects of extracellular HSPs 
Extracellular stress proteins of the Hsp and Grp families have powerful 
effects on the immune response (Srivastava, 2000; Calderwood et al., 2005). These 
stress proteins interact with the immune response in a number of contexts. 
Mammalian cells express HSPs at high levels after trauma or exposure to bacterial 




can act pro-inflammatory and lead to increased cytokine synthesis and release 
(Asea et al., 2000b; Asea et al., 2002). In addition, HSPs can stimulate adaptive 
immune response through their ability to bind antigenic peptides during antigen 
processing (Noessner et al., 2002). When Hsp-peptide complexes are released from 
dead and dying cells, they bind to receptors on antigen processing cells. Antigens 
can then be delivered to MHC class I molecules on the surfaces of  antigen 
processing cells through a process known as antigen cross-presentation (Arnold-
Schild et al., 1999; Singh-Jasuja et al., 2000). However, HSPs can also act anti-
inflammatory and their anti-inflammatory actions  are noticed specifically in 
inflammatory diseases. Diseases such as rheumatoid arthritis can be triggered by 
cross reactive T cells which recognize common epitopes in mammalian and highly 
immunogenic prokaryotic HSPs (van Eden et al., 2005; Hauet-Broere et al., 2006). 
It was speculated that high degree of sequence homology between prokaryotic and 
mammalian HSPs may be a factor triggering an autoimmune response to 
mammalian HSPs. Interestingly, however, application of some mammalian Hsp can 
suppress pro-inflammatory responses to bacterial Hsp epitopes and leads to 
remission of inflammatory diseases (Kingston et al., 1996). Thus, depending on 
context, extracellular HSPs can act both profoundly immunostimulatory and 
immunosuppressively, implying their dual immunoregulatory role (Daniels et al., 
2004; van Eden et al., 2005). In line with this observation, there is growing 
evidence that two extracellular HSPs (eHsp60 and eHsp70) are capable of 
activating pro-inflammatory responses, which can exacerbate diseases, such as 
atherosclerosis (Camici, 2002; Pockley et al., 2003) and coronary heart disease 
(Pockley et al., 2000; Zebrack & Anderson, 2002), but can also act beneficially, to 
facilitate recovery from bacterial infection (Campisi et al., 2002). 
As yet, there are no data in the literature on human HSPs induction and 
extracellular release related to trauma-exposure or to PTSD. However, given that 
psychological stressors have been shown to increase both intracellular and 
circulating levels of HSPs (Lewthwaite et al., 2002; Fleshner et al., 2004) thus 




is tempting to assume that trauma-exposure and/or PTSD might be associated 
with alterations in HSPs levels and consequent changes of inflammatory status. 
1.5.2 Mechanisms of Hsp70 release 
Hsp70 is not secreted by the classical pathway, since its sequence encodes no 
secretion leader signal. However, a number of non-canonical pathways for release 
of “leaderless” proteins exist. In some cases release of leaderless proteins involves 
cell lysis and this may occur both in pathological conditions that give rise to 
necrosis or in physiological conditions (Wewers, 2004). For instance, it has been 
suggested that Hsp70 may be released into the blood stream under a number of 
pathological conditions that lead to widespread cell death (Pockley, 2002). A 
second pathway involves release of intracellular proteins by extracellular 
membrane vesicles (De Maio, 2011). Stress proteins such as Hsp27, Hsp70, Hsc70 
and Hsp90 can apparently be released within the lumen of exosomes through such 
pathway when B cells are exposed to heat shock (Clayton et al., 2005). The 
postulation of vesicles or exosomes as a source of extracellular Hsp70 requires 
that these structures should rupture or lyse on entering the extracellular 
microenvironment (MacKenzie et al., 2001). A third secretion pathway involves the 
entry of the leaderless protein into secretory lysosomal endosomes, migration of 
these organelles to the cell surface and release of the contents of the endolysosome 
into the extracellular space (Baraldi et al., 2004). Indeed, Hsp70 has recently been 
shown to be secreted from tumor cells and macrophages by this pathway 
(Mambula & Calderwood, 2006). Study of these processes is still in its infancy and 
further studies are required to determine the favored pathways for Hsp70 release 
by neuronal and immune cells. 
1.5.3 Hsp70 uptake mechanisms 
HSPs interact with a range of cell surface receptors on target cells, most 
notably CD14, CD40 and Toll-like receptors (TLRs). It was proposed that CD91 




common receptor for all immunogenic HSPs, including Hsp60 and Hsp70 (Binder 
et al., 2000; Basu et al., 2001). However, its role as a direct high/medium affinity 
Hsp binder is still not clear. In addition, CD40 can also function as an Hsp70 
receptor (Wang et al., 2001). CD40 is a member of the tumor necrosis factor 
receptor family and plays a major role in antigen presenting cell maturation 
(Baraldi et al., 2004). However, the exact role of CD40 as a direct binder for 
mammalian HSPs is still a matter of debate. 
TLRs are subject of current investigations as potential Hsp receptors. The 
TLR couples exposure to prokaryotic “danger signals” (bacterial 
lipopolysaccharide, lipopeptides, CpG DNA) with intracellular signal transduction 
pathways that include the NF-κB and interferon signaling pathways (Takeda et al., 
2003). There are now at least 11 members of the TLR family, most of which have 
not been tested for Hsp binding. However, at least two TLR family members 
function as Hsp receptors and can couple the binding of Hsp60, Hsp70 and Grp96 
to NF-κB activity (Asea et al., 2000a; Asea et al., 2002; Quintana & Cohen, 2005). In 
addition, the cell surface protein CD14 is also required for induction of cytokines 
TNF-α, IL-1β and IL-6 by Hsp70 (Asea et al., 2000a). However, some studies 
suggest that the interactions between Hsp70 and TRL probably do not involve 
direct binding of Hsp70 to CD14, TLR2 or TLR4, since null cell that stably 
expresses CD14, TLR2 or TLR4 doesn’t bind avidly to Hsp70 (Theriault et al., 
2005). 
1.5.4 Hsp60 as intercellular signaling molecule 
The usual view of eukaryotic HSPs is that they are intracellular molecules 
that are released from necrotic, but not apoptotic cells, and that their release into 
(and presence in) the extracellular environment reflects pathophysiological state. 
For example, the circulating level of Hsp60 is significantly elevated in subjects who 
show signs of atherosclerosis. However, human Hsp60 induces the expression of 
the adhesion molecules E-selectin, intracellular adhesion molecule (ICAM-1) and 




the secretion of IL-6 from vascular endothelial cells, smooth muscle cells and 
macrophages (Kol et al., 1999; Kol et al., 2000). Furthermore, bacterial and 
mycobacterial HSPs induce proinflammatory cytokine expression (Peetermans et 
al., 1994; Galdiero et al., 1997) and bacterial Hsp60 (termed GroEL) induces 
expression of ICAM-1 and VCAM-1 in vascular endothelial cells (Galdiero et al., 
1997). The findings showing that proteins of the Hsp60 family could induce 
adhesion molecule expression and cytokine secretion from various cell types 
prompted the search for Hsp60 receptor. The CD14 antigen has been identified as 
the receptor for this protein on human peripheral blood mononuclear cells and 
coenocytes. Therefore, it seems that Hsp60 uses the signaling pathway also used 
by lipopolysaccharide (Kol et al., 2000). It was also shown that TLR4 (Ohashi et al., 
2000), which is an important mediator of innate immunity and lipopolysaccharide 
signaling in mouse cells, is needed for Hsp60 signaling (Hoshino et al., 1999). Data 
from another study (Vabulas et al., 2001) suggest that Toll-like receptor 2 plays a 
part in human Hsp60 signaling. More recent studies of human Hsp60 have 




2. The aims of the research 
The aim of the present study was to relate the parameters of inflammatory 
status with circulatory levels of HSPs and cortisol, and to uncover possible 
associations between inflammatory markers and extracellular HSPs with 
trauma-exposure, PTSD symptoms, vulnerability and resilience to PTSD. Toward 
that end the relevant parameters were determined in patients with current PTSD 
and life-time PTSD, in trauma-exposed individuals without PTSD and in 
non-traumatized healthy subjects. The measured parameters were: circulatory 
levels of a number of cytokines and CRP, as inflammatory markers; intracellular 
levels of HSPs Hsp90, Hsp70, Hsp72 and Hsp60; plasma levels of HSPs Hsp70, 
Hsp72 and Hsp60; plasma levels of cortisol before and after suppression of HPA 
axis by dexamethasone and the level of corticosteroid receptor proteins (GR and 
MR) in peripheral blood mononuclear cells.  
Specific aims of the study were: 
1. To learn whether excessive inflammation is associated with PTSD or with 
trauma, as an essential component of the disorder; 
2. To determine whether the intensity of inflammation correlates with PTSD 
symptoms, trauma exposure, vulnerability to PTSD, resilience to the 
disorder and/or with its remission; 
3. To reveal the relationship between extracellular HSPs and inflammatory 
status in all study groups.  
4. To examine the relation of plasma cortisol level and the lymphocyte level 
of corticosteroid receptors with inflammatory markers, trauma exposure, 
and vulnerability/resilience to PTSD. 
The results of the present study are expected to provide new insight into 
relationship of inflammation with PTSD pathology, trauma and 
vulnerability/resilience to PTSD, as well as to unravel possible causal role of 




3. Materials and Methods 
3.1 Subjects 
3.1.1. Study groups 
The study was performed on four groups of subjects: war veterans with 
current PTSD (current PTSD group, n = 133), veterans with life-time PTSD 
(life-time PTSD group, n = 66), those with war-related traumatic experiences but 
without PTSD, herein referred to as “trauma controls” (n = 102) and healthy 
controls (n = 99). All the participants in the study were male and were recruited in 
Serbia in the period from March 2005 to June 2008. PTSD patients were recruited 
from the Association of Veterans of Wars after 1990, the Association of ex-detained 
persons and war victims assessed or treated in the International Aid Network non-
governmental organization. Trauma control subjects were selected from the 
Association of Veterans of Wars after 1990 and from the Special Forces via the 
Military Medical Academy. Healthy subjects were found through available social 
networks, national trade unions and from the general population with the 
assistance of the Strategic Marketing Agency. The groups were matched by age and 
educational level. 
The inclusion criteria for subjects with current or life-time PTSD included: 
(1) exposure to war traumatic event(s); (2) current PTSD or life-time PTSD as 
defined by the DSM-IV criteria and assessed by the SCID-I and CAPS-DX and 
(3) CAPS Criteria A-F satisfied, with the score of B+C+D subtotals above 50. 
Trauma controls had no diagnosis of current or life-time PTSD, and did not fulfill 
CAPS Criteria A-F, the score of B+C+D subtotals being below 30. For the healthy 
control group the inclusion in the study required: no exposure to traumatic war 
event(s) and no diagnosis of current or life-time PTSD. 
The Clinician Administered PTSD Scale CAPS-DX (Paunovic & Ost, 2005) was 
used for diagnosing PTSD. Subjects with satisfied CAPS criteria A-F and a total 
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CAPS score higher or equal to 50 were classified in current or lifetime PTSD group, 
depending on whether the PTSD symptoms were current or lifetime. Those scoring 
less than 30 were classified in the trauma control group. The latter group differed 
from the healthy control group by fulfilling CAPS-DX criterion A. The subjects 
belonging to trauma control and healthy control groups had no diagnosis of PTSD. 
The exclusion criteria for all the groups included: (1) serious medical illness, 
(2) current psychotic disorder, as defined by DSM-IV criteria (except major 
depression), (3) current psychoorganic syndrome, as defined by DSM-IV criteria, 
(4) alcohol/substance dependence or abuse within 6 months prior to the entry 
procedure and (5) endocrinological or neurological illnesses likely to interfere 
with HPA axis function. 
Since PTSD is frequently co-morbid with depression, the severity of 
depression was assessed by the Beck’s Depression Inventory II (BDI-II), a 21-item 
multiple-choice self-report instrument (Beck, 1996). 
The washout period for medications, such as benzodiazepines, 
antidepressants, neuroleptics and antipsychotics, was at least 4 weeks prior to the 
entry procedure. 
Cigarette smoking and former alcohol consumption were assessed 
extensively in a clinical interview by the physician. These variables (the number of 
years of smoking, the number of cigarettes per day; the number of years, average 
quantity and frequency of drinking), introduced as covariates, did not influence 
any correlations of cortisol measures with other variables of interest and were not 
included in the analyses presented. 
 
3.1.2. Procedure 
This study is a part of a multidisciplinary FP6 research project 
“Psychobiology of Post-Traumatic Stress Disorder” performed by the international 
consortium “SPIN”. Only the data relevant to the title of this thesis are presented 
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herein. For the purpose of the whole study, the participants were hospitalized for 
2.5 days at the Institute for Endocrinology, Diabetes and Metabolic Diseases, 
University Clinical Centre of Serbia, Belgrade, and were subjected to simultaneous 
psychological and biological investigations. On admission to the hospital, the 
participants were first submitted to a comprehensive medical check-up, including 
a detailed anamnestic interview by a physician. Subsequently the blood sample 
was drawn for the analyses done within this part of the study. 
The study was approved by the Ethics Committee of the University Clinical 
Center of Serbia, Belgrade. All the participants signed a written informed consent 
after they were given a detailed written and verbal description of the study and the 
procedure they were subjected to. 
3.2 Reagents and antibodies 
Bovine serum albumine (BSA) and polyxyethylene-sorbitan monolaurate 
(Tween 20) were from SERVA (Germany), and tetramethylbenzidine was a product 
of BioLegend (USA). Human standard proteins, Hsp60 (200 µg) (ADI-NSP-540-E) 
and Hsp70/Hsp72 (200 µg) (ADI-NSP-555-D), were obtained from Enzo Life 
Sciences (Victoria, Canada). 
The primary antibodies used in this study are: rabbit polyclonal antibody 
against GR (PA1-511A), mouse monoclonal antibody against mineralocorticoid 
receptor (MR) (MA1620), both purchased from Affinity BioReagents; mouse 
monoclonal primary anti-Hsp60 antibody (ADI-SPA-806-F, clone LK-1), rabbit 
polyclonal anti-Hsp60 antibody (ADI-SPA-805-F), mouse monoclonal 
anti-Hsp70/Hsp72 antibody (ADI-SPA-810-F, clone C92F3A-5), rabbit polyclonal 
anti-Hsp70/Hsp72 antibody (ADI-SPA-812-F), mouse monoclonal antibody against 
Hsc70/Hsp70 (ADI-SPA-820-F, clone N27F3-4), mouse monoclonal antibody 
against Hsp90 (ADI-SPA-830-F, clone AC88), all from Stressgene. Secondary 
antibodies used in this thesis are goat anti-rabbit IgG polyclonal antibody horse-
radish peroxidase (HRP) conjugate (ADI-SAB-300-J), Enzo Life Sciences (Victoria, 
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Canada) and mouse and rabbit alkaline phosphatase (AP)-conjugated secondary 
antibody (Amersham Pharmacia Biotech). 
3.3 Preparation of blood plasma samples 
Samples of peripheral blood (40 ml) for most of the analyses described 
herein were obtained by venipuncture into heparin anticoagulant between 8:30 
and 9:30 a.m.  on the day of admission to the hospital. For plasma cortisol 
measurements before and after dexamethasone administration, the blood samples 
were drawn at 9:00 a.m. on the second and third day of hospitalization, 
respectively. 
3.4 Isolation of peripheral blood mononuclear cells  
PBMCs were isolated from whole blood by Ficoll-Paque PLUS (Amersham) 
density gradient centrifugation. The blood was first diluted with PBS buffer 
(1.5 mM KH2PO4, 6,5 mM Na2HPO4, 2,7 mM KCl, 0,14 M NaCl, pH 7,2) in 2:1 ratio, in 
order to avoid aggregation of eritrocytes. Diluted blood was layered over the 
Ficcol, and the samples were centrifuged at 380 x g for 30 min at 20°C. After 
centrifugation the distinct layers are obtained: upper layer that contains blood 
plasma, interface with lymphocytes and ficoll layer with the pellet consisting of 
granulocytes and erythrocytes. The blood plasma was isolated and stored at -70ºC 
for subsequent processing. A portion of mononuclear cells, recovered from the 
plasma/Ficoll interface was immediately frozen liquid nitrogen and stored until 
use. 
3.5 Preparation of whole cell extracts 
For the whole cell extract preparation, PBMCs, stored in liquid nitrogen, were 
resuspended and incubated (15 min, 0°C) in ice-cold TEDG buffer (10 mM Tris, 1 
mM ethylenediaminetetraaceticacid, 2.5 mM dithiothreitol, 10% glycerol, 0.1 mM 
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phenylmethylsulphonylfluoride, pH 7.4), sonicated (2 x 15 s, 1A, 50/60 Hz, 30% 
amplitude, Hielscher Ultrasound Processor) and centrifuged (14000 x g, 20 min, 
4°C). The supernatants, referred to as whole cell extracts, were analyzed for total 
protein content by the method of Spector (1978). 
3.6 Plasma cortisol measurements 
Plasma cortisol concentrations were determined by RIA (CORT-CT2, CIS 
biointernational, Gif-Sur-Yvette Cedex, France). Minimal detectable concentration 
was 4.6 nmol/L, while intra- and inter-assay variations were below 5.4% and 
7.3%, respectively.  
We chose nocturnal cortisol levels as better representation of the resting 
state than the day values, because of the reduced external stimuli during the night. 
Basal cortisol is represented by individual mean values obtained from 13 
night/morning time points. 
Dexamethasone suppression test (DST) is used to test the self-regulation of 
HPA axis by cortisol via GR. The usual dexamethasone doses applied are 1 mg 
(considered high) and 0.5 mg (considered low). In this study, the DST was 
performed with the low dose (0.5 mg), which was applied at midnight. For 
assessment of HPA axis suppression, plasma cortisol values determined at 9:00 
a.m. on two consecutive days were compared. The first value was determined prior 
to dexamethasone administration (preDEX cortisol) and the second after 
dexamethasone administration (postDEX cortisol). Cortisol suppression is 
expressed as percent of suppression and was calculated as follows: 
% suppression = [(pre-DEX cortisol – postDEX cortisol)/preDEX cortisol] x 100.  
3.7 Determination of eHsp70 concentration by ELISA 
The level of extracellular inducible Hsp70 (Hsp72) in blood plasma was 
determined by commercial sandwich ELISA (enzyme-linked immunosorbent 
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assay) according to the manufacturer's instructions (Enzo Life Sciences). Briefly, 
precoated plates were blocked with 250 μl of blocking buffer (PBS, pH 7.3, 
containing 1% BSA) for 2 h at 25°C on a shaker. After washing with PBST, Hsp70 
standards (100 μl; 0–2500 ng/ml in PBS) or samples (plasma) were added and 
incubation proceeded for 2 h at 25°C on with shaking. Plates were washed four 
times and 100 μl of rabbit polyclonal anti-Hsp70 antibody was added. After 1 h at 
25°C on a shaker, plates were washed and incubated with 100 μl of anti-rabbit IgG 
polyclonal antibody HRP-conjugate for 1 h at 25°C on a shaker. The wells were 
washed six times and 100 μl of the substrate solution (TMB) was added and 
incubated at room temperature in the dark for 15 min. The reaction was stopped 
using 50 μl of 1 M H3PO4. Absorbance was read at 450 nm and 650 nm on the 
Multiscan Spectrum (Thermo Electron). Results were expressed as ng of eHsp72 
per ml of plasma. 
In parallel, the level of constitutive Hsp70 (Hsc70) in blood plasma was 
determined by the sandwich ELISA procedure reported by Njemini et al. (2005), 
with slight modification. In this protocol plates were coated with the primary 
antibody, anti-Hsp70/Hsc70 (SPA-820) (50 μl; 2 μg/ml), diluted in 0.1 M 
carbonate buffer (15 mM Na2CO3, 35 mM NaHCO3, 3 mM NaN3, pH 9.6). After 
overnight incubation on 4°C, the coated plates were washed four times with PBST 
and non-specific binding sites were blocked with 300 μl of blocking buffer (PBS, 
pH 7.3, containing 1% BSA) for 2 h at 25°C on a shaker. After washing with PBST, 
Hsp70 standards (50 μl; 0–2500 ng/ml in PBS) or samples (plasma) were added 
and incubation proceeded for 2 h at 25°C on a shaker. Plates were washed four 
times and 50 μl of rabbit polyclonal anti-Hsp70 antibody (ADI-SPA-812) (2 μg/ml) 
diluted in PBST was added. After 1 h at 25°C on a shaker, plates were washed and 
incubated with 50 μl of anti-rabbit IgG polyclonal antibody HRP conjugate in 
PBS/T (50 ng/ml) (ADI-SAB-300-J) for 1 h at 25°C on a shaker. The wells were 
washed six times and 50 μl of the substrate solution TMB was added and incubated 
at room temperature in the dark for 15 min. The reaction was stopped using 30 μl 
of 1 M H3PO4. Absorbance was read at 450 nm on the Multiskan Spectrum (Termo 
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Electron Corporation), subtracted from values at 650 nm and results were 
expressed as ng of eHsp70 per ml of plasma. 
3.8 Determination of eHsp60 concentration by ELISA 
The level of extracellular Hsp60 in blood plasma from the four groups of 
patients was determined by sandwich ELISA developed in our laboratory. Briefly, 
the 96-well plates were coated with the mouse primary anti-Hsp60 antibody 
(ADI-SPA-806) (50 μl; 4 μg/ml) diluted in 0.1 M carbonate buffer (15 mM Na2CO3, 
15 mM NaHCO3, 3 mM NaN3, pH 9.6). After overnight incubation at 4ºC, the coated 
plates were washed four times with phosphate-buffered saline (PBS) (135 mM 
NaCl, 40 mM Na2HPO4 x 2H2O, 1 mM KH2PO4, 3 mM KCl) containing 
0.1% Tween-20 (PBST). Non-specific binding sites were blocked with 300 μl of 
blocking buffer (PBS, pH 7.3, containing 1% BSA) for 2 h at 37ºC on a shaker. After 
washing with PBST, Hsp60 standards (50 μl; 0–40 μg/ml in PBS) or samples 
(plasma) were added and incubation proceeded for 2 h at 37ºC on a shaker. Plates 
were washed four times and 50 μl of rabbit polyclonal anti-Hsp60 antibody 
(ADI-SPA-805) (2 μg/ml) diluted in PBST was added. After 1 h at 37ºC on a shaker, 
plates were washed and incubated with 50 μl of anti-rabbit IgG polyclonal HRP 
conjugate antibody in PBST (200 ng/ml) (ADI-SAB-300-J) for 1 h at 37ºC with 
gentle shaking. The wells were washed six times and 50 μl of the substrate solution 
(tetramethylbenzidine) was added and incubated at room temperature in the dark 
for 15 min. The reaction was stopped using 30 μl of 1 M H3PO4. Absorbance was 
read at 450 nm on the Multiskan Spectrum (Termo Electron Corporation), 
subtracted from values at 650 nm and results were expressed as µg of Hsp60 per 
ml of plasma. 
3.9 Determination of plasma cytokine levels 
FlowCytomix™ Multiplex Kit developed by Bender MedSystems (BMS810FF, 
eBioscience) was used in this study in order to simultaneously quantify 11 
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cytokines (IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p70), TNF-α, TNF-β) 
in the blood plasma from the study participants. A FlowCytomix™ Multiplex assay 
represents a unique sandwich immunoassay. Namely, the kit contains fluorescent 
bead sets, each pre-coated with an antibody unique for one cytokine. Within two 
bead size populations, A and B (4 μm and 5 μm, respectively), there are multiple 
bead subsets, differentiated by varying intensities of an internal fluorescent dye. 
The dye can be excited by an Argon or He-Ne laser, and emits at 690 nm (the far 
red spectrum). The combination of the two different bead sizes and different 
internal dye intensities makes it possible to distinguish 11 bead sets in one 
fluorescent channel. 
In our experiments, antibody-coated beads were added and incubated with 
plasma sample. Target analytes in plasma sample were captured by specific 
antibodies on each bead set. After 1 h of incubation and subsequent washing, a 
biotin-conjugated secondary antibodies specific for bound analytes were added. 
Following 2 h of incubation and washing, streptavidin-PE was added for detection 
of biotin-conjugated antibody. Streptavidin-PE, which binds to the biotin 
conjugate, emits at 578 nm, allowing the quantification of the analyte. Detection 
was performed by flow cytometry, which differentiates bead populations 
according to bead size and fluorescent signature. Concentration of each cytokine 
was determined using 5PL curve and the results were expressed as pg of specific 
cytokine per ml of blood plasma. 
In most blood plasma samples, irrespectively of the study group, the levels of 
IL-1β and TNF-β were under the limits of the detection. Therefore, the results for 
these two cytokines are not presented herein. 
3.10 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)  
After boiling in 2x Laemmli's buffer (Laemmli, 1970), 40 µg of PBMC whole 
cell extracts were separated on 10 % gels by SDS-polyacrylamide gels 
electrophoresis (SDS-PAGE) overnight, at 120 V and at 4°C. Myosin (205 kDa), b-
galactosidase (116 kDa), phosphorylase b (97 kDa), bovine serum albumin 
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(66 kDa) and carbonic anhydrase (29 kDa) were simultaneously run as molecular 
mass references. 
3.11 Western blotting 
Western transfer of proteins from the gels to polyvinylidene fluoride 
membranes was carried out overnight at 135 mA and 4°C in 25 mM Tris buffer, 
pH 8.3, containing 192 mM glycine and 20% (v/v) methanol. Unbound sites on the 
membranes were blocked by 1 h incubation at room temperature in PBS 
containing 0.5% nonfat dry milk. The membranes were then respectively probed 
with antibody against GR (PA1-511A; 1:1000), MR (MA1-620; 1:1000), inducible 
Hsp70/Hsp72 (SPA-810, 1:500), constitutive Hsp70/Hsc70 (SPA-820; 1:100), 
Hsp60 (SPA-805; 1:500); Hsp90 (ADI-SPA-830; 1:1000) by overnight incubation at 
4ºC. Subsequently, the membranes were incubated 1.5 h at room temperature with 
antibody against β-actin (AC-15, 1:20000), which was used as equal loading 
control. After washing with PBS containing 0.1%  Tween 20 the membranes were  
incubated with appropriate AP-conjugated secondary antibody (1:20000) under 
the same conditions. Probing for each protein was followed by stripping with 0.2 M 
NaOH and blocking. Immunopositive bands were visualized by an enhanced 
chemifluorescent method using STORM scanner (Amersham). Relative optical 
density of immunoreactive bands was determined by ImageQuant software (GE 
Healthcare). In order to make quantitative comparisons between multiple 
immunoblots reliable, an internal reference sample, obtained from a healthy blood 
donor, was run on each gel in triplicate: in the middle and both ending lanes. The 
intensity of each analyzed immuno-specific band was normalized to the intensity 
of the nearest internal reference band on the same blot and also to the intensity of 
β-actin band in the same lane.  
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3.12 Depletion of albumin from blood plasma 
For the purpose of validation of in-house ELISAs by Western blot, it was 
necessary to remove albumin from plasma beforehand. In order to deplete 
albumin from plasma samples we performed a fractionation of the plasma proteins 
with increased concentrations of ammonium sulfate according to Jiang et al. 
(2004). Aliquot of plasma, containing 2 mg of total protein, was diluted with PBS to 
500 μl and ammonium sulfate was added to reach 30% saturation. After gentle 
vortexing for 10 min, the sample was left at room temperature for 1 h and 
centrifuged at 10 000 xg, 20°C, for 30 min. The supernatant was transferred to 
another tube and ammonium sulfate was added to reach 50% saturation. The 
mixture was treated as above. The proteins in the supernatant were further 
fractionated with 70% and 90% ammonium sulfate saturation. Each of the four 
pellets was washed with 300 μl of ice cold 90% acetone, dried in air and suspended 
in 200 μl of 2x Laemmli’s sample buffer. Protein concentration in the blood plasma 
samples was determined by a Coommassie staining procedure as described by 
Spector (1978).  
3.13 Validation of ELISA by Western blotting 
In order to test specificity of the antibody used in in-house ELISAs for eHsp60 
and eHsp70, we performed Western blotting with plasma samples depleted of 
albumin. After each ammonium sulfate-fractionation step 50 μl of supernatant was 
collected, mixed 1:1 with 2x Laemmli’s sample buffer and boiled for 5 min. All 
samples were subjected to SDS-PAGE and Western blot analysis using rabbit 
polyclonal anti-Hsp60 antibody (ADI-SPA-805-F) and mouse monoclonal antibody 
against Hsc70/Hsp70 (ADI-SPA-820-F, clone N27F3-4). These experiments 
demonstrated that the best immunoreactive bands corresponding to Hsp60 or 
Hsp70, respectively, were observed in plasma fractions obtained after 70% 
ammonium sulfate saturation. 
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3.14 Determination of cytokines by multiplex ELISA 
FlowCytomix™ Multiplex Kit developed by Bender MedSystems (BMS810FF, 
eBioscience) is used in this study in order to simultaneously quantify 11 cytokines 
(IFN-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p70), TNF-α and TNF-β) in the 
human plasma of the four studied groups. A FlowCytomix™ Multiplex assay 
represent a unique sandwich immunoassay. Namely, the kits contain fluorescent 
bead sets, each pre-coated with an antibody unique for one cytokine. Within two 
bead size populations, A and B (4 μm and 5 μm, respectively), there are multiple 
bead subsets, differentiated by varying intensities of an internal fluorescent dye. 
The dye can be excited by an Argon or He-Ne laser, and emits at 690 nm (the far 
red spectrum). The combination of the two different bead sizes and different 
internal dye intensities makes it possible to distinguish 11 bead sets in one 
fluorescent channel. 
In our experiments, antibody-coated beads are added and incubated with 
plasma sample. Target analytes in plasma sample are captured by specific 
antibodies on each bead set. After 1 h of incubation and subsequent washing, a 
biotin-conjugated secondary antibodies specific for bound analytes are added. 
Following 2 h of incubation and washing, streptavidin-PE is added for detection of 
biotin-conjugated antibody. Streptavidin-PE, which binds to the biotin conjugate, 
emits at 578 nm, allowing the quantification of the analyte. For detection was 
performed by flow cytometry, which differentiate bead populations according to 
bead size and fluorescent signature. Concentration of all cytokines is determined 
using 5PL curve and the results are expressed as pg of specific cytokine per ml of 
plasma. In most of the plasma samples, irrespective of the study groups, the levels 
of two cytokines, IL-1β and TNFβ, were below the detection limit of the assay and 
the results are not presented. 
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3.15 Statistical analyses 
Data analyses were done using SPSS, version 17.0. Variables were tested for 
normality by Kolmogorov-Smirnov test, which confirmed normal distribution. The 
values were considered outliers and were excluded if standardized z-scores fell 
outside the range of ±3.29. Between-group differences were assessed by one-way 
analysis of variance (ANOVA) and p values were considered statistically significant 
at the level of less than 0.05 (two-tailed). When ANOVA test revealed a significant 
main effect, Bonferroni post hoc test was used for multiple between-group 
comparisons. The group means are expressed as mean ± standard deviation (SD). 
Possible influence of co-morbid depression on group differences in the tested 
variables was assessed by analysis of covariance (ANCOVA), or by partial 
correlation analysis, taking BDI-II score as a covariate. 
The Pearson’s correlation coefficients were compared between groups by 
converting correlation coefficients to zr, calculating z-score and determining 





4.1. Demographic characteristics of the study groups 
Demographic characteristics of the study groups are summarized in Table 
4.1. The groups were matched by age (43.6 ± 9.3, mean ± SD) and educational level 
(11.7 ± 2.4 years of education, mean ± SD). All traumatic experiences were related 
to the recent wars in the Balkan region. The average number of early traumatic 
events and the mean body mass index did not differ between the groups. All the 
groups had a similar average number of smokers vs. nonsmokers (data not shown), 
but the life-time PTSD group differed from the healthy control group in the number 
of cigarettes smoked per day. Therefore, this variable was analyzed as a covariate 
whenever it was necessary. 
As expected, the total score on CAPS diagnostic tool for PTSD was 
significantly higher in all three traumatized groups in comparison to healthy 
control group, and in two PTSD groups in comparison to trauma controls. Among 
the three traumatized groups of participants, the highest number of traumatic 
experiences was registered in current PTSD group. The average score on Beck’s 
Depression Inventory II was significantly higher in current and life-time PTSD 
groups than in trauma control group or healthy control group, while the two 
control groups did not differ in respect to BDI II score. These data showed that in 
our sample depression was frequently comorbid with current PTSD and even with 


















Group comparisons were done by one-way ANOVA followed by post hoc Bonferroni test. 
 N, number of subjects per group; BMI, body mass index; CAPSTOT, total CAPS score; uPRSaTOT, number of traumatic events; BDITOT, total BDI II score; 
*, significantly different from healthy controls; 
 # significantly different from trauma controls. 
 
 
N Current PTSD Life-time PTSD Trauma controls 
   Healthy 
   controls 
  ANOVA 
      Mean ± SD    Mean ± SD       Mean ± SD Mean ± SD F p 
Age (years) 132 44.1 ± 8.7 42.9 ± 10.3 42.9 ± 8.9 42.6 ± 10.2 0.16 0.930 
BMI (kg/m2) 132 27.5 ± 3.9       26.6 ± 4.4 27.5 ± 3.9 27.6 ± 3.0 0.45 0.720 
Cigarettes/day   97  30  ± 16    34 ± 18*    26 ± 11 22 ± 8 3.20 0.025 
CAPSTOT 132     61.8 ± 10.1*#    25.6 ± 6.9*#    13.8 ± 9.4*  5.3 ± 6.8 286.50 0.001 
uPRSaTOT 130      65.8 ± 30.8*#    48.9 ± 31.9*      44.0 ± 23.4* 0.1 ± 0.5   41.30 0.001 




4.2. Plasma cortisol level and HPA axis sensitivity 
Cortisol, as the marker of HPA axis activity, was assessed in the blood plasma 
samples from all the participants in the study. Cortisol was measured in the clinical 
setting every hour during night, starting from 10 p.m. until 9 a.m. the next day, plus 
an additional sample at 7:30 a.m. to follow the morning rise of HPA axis activity. 
We chose nocturnal cortisol levels as a better representation of the resting state 
than daily values, because of the reduced external stimuli during night. The group 
means were calculated from the individual mean values of cortisol level derived 
from 13 measurements and taken as basal cortisol level. 
Between group differences in basal cortisol level were not observed (one-
way ANOVA, F= 2.39, p= 0.072) (Figure 4.1). 
 
Figure 4.1. Basal plasma level of cortisol. Plasma level of cortisol was 
measured hourly during night. The individual means calculated from 13 
measurements were used to obtain group means (CORTMEAN), which were 
taken as average basal cortisol levels. The results are expressed as means ± SD.  
The release of cortisol from the adrenal gland is regulated by the hormone 
ACTH, so that its level is considered as an additional marker of HPA axis activity. 
ACTH level was assessed during night, at the same time points as cortisol, every 
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hour starting from 10 p.m. to 9 a.m. the next day. The individual mean values of 
ACTH were calculated on the basis of 13 nocturnal/morning measurements. 
Group means of ACTH level, calculated from individual values, were not 
significantly different among the study groups (one-way ANOVA, F= 0.67, p= 
0.573) (Figure 4.2). 
Figure 4.2. Plasma level of ACTH. Plasma level of ACTH was measured hourly 
during night. The individual means calculated from 13 measurements were used 
to obtain group means (ACTH mean). The results are expressed as means ± SD. 
In order to test regulation of HPA axis activity i.e. to assess its sensitivity to 
feed-back inhibition by cortisol, we performed dexamethasone suppression test 
(DST) in all study groups. The plasma level of cortisol was assessed at 9 a.m. and 
designated as preDEX cortisol value. Dexamethasone was administered orally at 
the dose of 0.5 mg, at midnight. The plasma cortisol level after dexamethasone 
administration (postDEX cortisol value) was measured at 9 a.m. the next morning. 
The percent of suppression of HPA axis by dexamethasone was calculated 
according to the formula [(preDEX cortisol − postDEX cortisol)/preDEX 
cortisol] × 100. The statistical analysis revealed that study groups were 
significantly different in respect to the degree of suppression (one-way ANOVA, F= 
6.011, p < 0.01). Bonferoni post hoc test indicated a significant differences between 
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current PTSD and healthy control groups (p < 0.0001), as well as between the 
life-time PTSD and healthy control groups (p = 0.038) (Figure 4.3). 
The results of DST show that HPA axis in patients with PTSD displays 
increased sensitivity to dexamethasone in comparison to healthy controls, which 
reflects increased HPA axis responsiveness to endogenous cortisol. Moreover, 
increased efficiency of feed-back inhibition of HPA axis is also a characteristic of 
life-time PTSD patients. Since both current and life-time PTSD patients are 
obviously vulnerable to PTSD, as they developed PTSD symptoms after exposure to 
trauma, this finding suggests that hypersensitivity of HPA axis to cortisol might be 
a biological correlate of vulnerability to PTSD. 
Figure 4.3. Suppression of HPA axis by dexamethasone. Plasma levels of 
cortisol were measured at 9 a.m. before and after a midnight oral 
dexamethasone administration at the dose of 0.5 mg. Percent of suppression of 
HPA axis was calculated by the formula: [(preDEX cortisol − postDEX 
cortisol)/preDEX cortisol] × 100, and the results are expressed as means ± SD. 
The level of statistical significance of between-group differences is presented by 
p value. 
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4.3 Corticosteroid receptors expression in the 
lymphocytes 
Western blot analysis of the GR protein in the whole cell extract of PBMCs 
demonstrated presence of two immuno-specific bands: one migrating at 97 kDa 
and the other at 105 kDa. The higher molecular mass GR band could be detected 
only in 52-57% of the subjects in each group and in majority of participants was 
considerably less abundant than the lower molecular mass band. Considering all 
groups together, in the lymphocytes of the individuals presenting 105 kDa GR 
band, the intensity of the 97 kDa band was significantly lower in comparison to the 
individuals missing the higher band (t-test, p < 0.001). It was also valid for each of 
the four groups of subjects separately. The intensity of both bands together 
revealed statistically significant increase in the average total GR protein level in 
PBMCs from current PTSD patients (p = 0.021) and life-time PTSD subjects (p = 
0.011) in comparison to trauma controls (Figure 4.4). Between-group differences 





 Figure 4.4. Relative level of GR in peripheral lymphocytes. (A) The GR was 
detected by Western blot using rabbit polyclonal anti-GR antibody. A 
representative blot is shown, containing two sets of four participants and three 
internal reference samples. Lanes: 1, 6, 11 – internal reference samples; 2, 7 – 
patients with current PTSD; 3, 8 – life-time PTSD patients; 4, 9 – trauma 
controls; 5, 10 – healthy controls. (B) Quantitative analysis was done by the 
ImageQuant software. The intensity of each analyzed immuno-specific band was 
normalized to the intensity of the nearest internal reference band on the same 
blot and to the intensity of β-actin band in the same lane. Relative integrated 
optical densities of both GR bands together (GRtotal) are expressed in arbitrary 
units (AU) as means ± SD. 
A similar semi-quantitative immunoblot procedure was applied for 
determination of the relative level of MR in peripheral lymphocytes from the four 
groups of subjects. Measuring relative integrated optical densities of the 
immunoreactive bands corresponding to the MR, a rather uniform expression level 
of the MR protein was noticed throughout all study groups (Figure 4.5). Statistical 
B 
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analysis did not reveal significant differences between the groups (ANOVA, F= 
0.56, p= 0.640). 
 
Figure 4.5. Relative level of MR in peripheral lymphocytes. (A) MR was 
detected using rabbit polyclonal anti-MR antibody. A representative blot is 
shown, containing two sets of four participants and three internal reference 
samples. Lanes: 1, 6, 11 – internal reference samples; 2, 7 – patients with current 
PTSD; 3, 8 – life–time PTSD patients; 4, 9 – trauma controls; 5, 10 – healthy 
controls. (B) Quantitative analysis was done by the ImageQuant software. The 
intensity of each analyzed immuno-specific band was normalized to the intensity 
of the nearest internal reference band on the same blot and to the intensity of 
β-actin band in the same lane. Relative integrated optical densities of MR bands 
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The balance between GR- and MR-promoted actions critically determines 
functioning of HPA axis. Analysis of protein levels of two corticosteroid receptors 
in the individual PBMC enabled us to calculate the MR/GR ratio in the lymphocytes. 
It was found that the ratio was not significantly different between the analyzed 
groups of subjects (ANOVA, F= 0.82, p= 0.487) (Figure 4.6). 
Figure 4.6. Relative ratio of MR and GR in peripheral lymphocytes. The 
results are expressed as means ± SD. 
4.4 Heat shock protein expression levels 
4.4.1 Heat shock protein levels in peripheral lymphocytes 
The level of Hsp90 expression in the PBMC whole cell extracts was 
determined by a semi-quantitative Western blot procedure. The results show very 
similar levels of Hsp90 protein in all study groups (Figure 4.7). The ANOVA 
analysis revealed that there are no statistically significant differences in the level of 







Figure 4.7. Relative level of Hsp90 in peripheral lymphocytes. (A) Hsp90 
was detected in the whole cell extract of PBMCs by a monoclonal anti-Hsp90 
antibody. A representative blot is shown, containing two sets of four participants 
and three internal reference samples Lanes: 1, 6, 11 – internal reference 
samples; 2, 7 – patients with current PTSD; 3, 8 – life–time PTSD patients; 4, 9 – 
trauma controls; 5, 10 – healthy controls. (B) Quantitative analysis was done by 
the ImageQuant software. The intensity of each analyzed immuno-specific band 
was normalized to the intensity of the nearest internal reference band on the 
same blot and to the intensity of β-actin band in the same lane. Relative 
integrated optical densities of Hsp90 bands are expressed in arbitrary units (AU) 
as means ± SD.  
 
The level of Hsp70 expression in PBMCs was also determined by 
semi-quantitative Western blot. For detection of the protein two different 
antibodies were used: one recognizing both constitutive (Hsc70) and inducible 
Current             Life-time           Trauma             Healthy 
   PTSD                PTSD               control             control 








(Hsp72) isoforms of Hsp70 (herein designated as Hsp70) and the other 
recognizing only the inducible isoform, Hsp72. Measurement of relative optical 
densities of the immunospecific bands corresponding to Hsp70 (Hsc70+Hsp72) in 
the PBMC whole cell extracts showed that the intracellular levels of Hsp70, 
including both constitutive and inducible isoforms, was not significantly different 
between the study groups (ANOVA, F= 1.81; p = 0.14) (Figure 4.8). 
Figure 4.8. Relative level of Hsp70 in peripheral lymphocytes. (A) The 
Hsp70 (Hsc70+Hsp72) was detected using rabbit polyclonal anti-Hsp70 antibody 
recognizing both constitutive and inducible isoforms of the protein. A 
representative blot is shown, containing two sets of four participants and three 
internal reference samples. Lanes: 1, 6, 11 – internal reference samples; 2, 7 – 
patients with current PTSD; 3, 8 – life–time PTSD patients; 4, 9 – trauma 
controls; 5, 10 – healthy controls. (B) Quantitative analysis was done by the 
ImageQuant software. The intensity of each analyzed immuno-specific band was 
normalized to the intensity of the nearest internal reference band on the same 
blot and to the intensity of β-actin band in the same lane. Relative integrated 
optical densities of Hsp70 bands are expressed in arbitrary units (AU) as 
means ± SD.  
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When the expression of inducible Hsp70 (Hsp72) in the whole cell extracts of 
PMBCs was examined by immunoblotting, it was found that the intracellular level 
of Hsp72 was not significantly different between the study groups ( ANOVA, F= 
2.06, p= 0.11) (Figure 4.9). 
Figure 4.9. Relative level of Hsp72 in peripheral lymphocytes. (A) Inducible 
isoform of Hsp70, Hsp72, was detected using rabbit polyclonal anti-Hsp72 
antibody, recognizing only the inducible isoform of the protein. A representative 
blot is shown, containing two sets of four participants and two internal reference 
samples Lanes: 1, 10 – internal reference samples; 2, 6 – patients with current 
PTSD; 3, 7 – life–time PTSD patients; 4, 8 – trauma controls; 5, 9 – healthy 
controls. (B) Quantitative analysis was done by the ImageQuant software. The 
intensity of each analyzed immuno-specific band was normalized to the intensity 
of the nearest internal reference band on the same blot and to the intensity of 
β-actin band in the same lane. Relative integrated optical densities of Hsp72 
bands are expressed in arbitrary units (AU) as means ± SD.  
Semi-quantitative immunoblot procedure was also applied to examine 
possible PTSD-and trauma-related alterations in the expression of Hsp60 in the 
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measurement of relative optical densities of the immunospecific bands 
corresponding to Hsp60 showed that the intracellular level of this HSP was not 
significantly different between the study groups (one-way ANOVA, F= 0.45, 
p= 0.72) (Figure 4.10). 
Figure 4.10. Relative level of Hsp60 in peripheral lymphocytes. (A) Hsp60 
was detected using rabbit polyclonal anti-Hsp60 antibody, followed by alkaline 
phosphatase-conjugated secondary antibody. Immunopositive bands were 
visualized by enhanced chemifluorescence. A representative blot is shown, 
containing two sets of four participants and two internal reference samples 
Lanes: 1, 10 – internal reference samples; 2, 6 – patients with current PTSD; 3, 7 
– life–time PTSD patients; 4, 8 – trauma controls; 5, 9 – healthy controls. (B) 
Quantitative analysis was done by the ImageQuant software. The intensity of 
each analyzed immuno-specific band was normalized to the intensity of the 
nearest internal reference band on the same blot and also to the intensity of 
β-actin band in the same lane. Relative integrated optical densities of Hsp60 
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Correlation analyses of the data showed that Hsp90 concentration in PBMCs 
was significantly correlated with the concentrations of both MR (r = 0.282, 
p < 0.0001) and GR (r = 0.362, p < 0.0001), whereas Hsp70 concentration was 
correlated only with MR concentration (r = 0.371, p < 0.0001). Similar results were 
obtained when the analyses were performed on each of the four study groups 
separately (Table 4.2). Between-group comparison of the Pearson’s correlation 
coefficients between Hsp90 and GR concentrations revealed a larger effect size in 
the trauma-exposed groups than in the healthy control group, as well as a smaller 
effect size of the correlation between Hsp70 and MR concentrations in the current 
PTSD group in comparison to trauma control group (Table 4.2). Additionally, it 
was found that the concentrations of the two examined HSPs were correlated 
(r = 0.390, p < 0.0001) without significant between-group differences in the effect 
size (Table 4.2), while the two corticosteroid receptor concentrations were not 
mutually related. Partial correlation analyses showed that co-morbid depression 
did not exert any influence on the relationship between the concentrations of 




Table 4.2. Statistically significant Pearson's correlation coefficients between the levels of HSPs and corticosteroid receptors 




























r 0.397    0.209    0.463*    
p <0.0001    0.030    <0.0001    
Lifetime 
PTSD 
r  0.444    0.308    0.401*   
p  <0.0001    0.016    0.019   
Trauma 
controls 
r   0.434    0.310    0.473*  
p   <0.0001    0.003    <0.0001  
Healthy 
controls 
r    0.347    0.322    0.217 




r     0.231#        
p     0.014        
Lifetime 
PTSD 
r      0.277       
p      0.029       
Trauma 
controls 
r       0.485      
p       <0.0001      
Healthy 
controls 
r        0.405     
p        <0.0001     
The number of participants per group: current PTSD, 113; life-time PTSD, 61; trauma controls, 88;healthy controls, 85. 
* sifnificantly different from healthy controls (current PTSD: Z = 1.92, p = 0.027; life-time PTSD: Z = 1.91, p = 0.021; trauma controls: Z = 1.90, 
   p = 0.029). 
# significantly different from trauma controls (current PTSD: Z = 1.98, p = 0.024. 




4.4.2 Plasma levels of heat shock proteins 
The level of extracellular HSPs (eHsp70, eHsp72 and eHsp60) were measured 
in blood plasma by commercial or home-made sandwich ELISA protocols, using the 
appropriate monoclonal and secondary antibodies. The level of extracellular 
Hsp70 (Hsc70+Hsp72) was assessed in 104 samples and ranged from 0.25 ng/ml 
to 80 ng/ml. The level of extracellular Hsp72 were determined in 118 plasma 
samples and ranged from 20 ng/ml to 90 ng/ml. 
Figure 4.11 demonstrates the level of eHsp70 in the blood plasma from 
current PTSD patients, life-time PTSD patients, trauma controls and healthy 
controls. The statistical analyses revealed that there are no significant differences 
between groups (ANOVA, F= 0.95, p= 0.420). 
Figure 4.11. Plasma level of Hsp70. The level of Hsp70 (Hsc70+Hsp72) in 
blood plasma was determined by an in-home sandwich ELISA. Plates were 
coated with the primary antibody, anti-Hsp70/Hsc70 (SPA-820), and the protein 
was detected by rabbit polyclonal anti-Hsp70 antibody (ADI-SPA-812). The 
results are expressed  as means ± SD. 
The level of inducible isoform, eHsp72, in blood plasma from current PTSD 
patients, life-time PTSD patients, trauma controls and healthy controls are 
displayed in Figure 4.12. Statistical analysis revealed that there are no significant 
differences between groups (ANOVA, F= 1.95, p= 0.120). 
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Figure 4.12. Plasma level of Hsp72. The level of extracellular inducible Hsp70 
(Hsp72) in blood plasma was determined by commercial sandwich ELISA 
according to the manufacturer's instructions (Enzo Life Sciences). The results 
are expressed as means ± SD. 
Interestingly, the correlation analyses have shown that there is a significant 
correlation (r = 0.469, p = 0.032) between the number of traumatic events and 
eHsp70 level only in the group of current PTSD patients.  
A total of 250 plasma samples were assayed for extracellular Hsp60, with 
89% (222 samples) being positive for the presence of this protein. Levels of Hsp60 
ranged from 0.2 µg/ml to 50 µg/ml, with the median level of 20 µg/ml. This wide 
range of Hsp60 concentrations in the circulation is in accordance with previously 
reported concentrations of Hsp60 found in human blood. It has been found that 
40-50% of the humans have no measurable eHsp60 in the blood plasma. The level 
of plasma Hsp60 in the remaining 50-60% men and women is measured in 
nanograms/ml or micrograms/ml, while in a small proportion of the population in 
milligrams/ml (Shamaei-Tousi et al., 2007). 
Our results show that the mean level of eHsp60 in current PTSD patients was 
20.31 ± 10.98 µg/ml, in life-time PTSD group 19.83 ± 10.76 µg/ml, in trauma 
controls 19.38 ± 11.22 µg/ml and in healthy controls 20.51 ± 11.84 µg/ml. No 
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significant differences in the level of extracellular Hsp60 were observed between 
the four study groups (ANOVA, F=0.11, p=0.95) (Figure 4.13). 
Figure 4.13. Plasma level of Hsp60. The level of eHsp60 in blood plasma from 
the four groups of subjects was determined by sandwich ELISA developed in our 
laboratory. Mouse primary anti-Hsp60 antibody (ADI-SPA-806) was used as 
capture antibody and rabbit polyclonal anti-Hsp60 antibody (ADI-SPA-805) was 
used as a detection antibody. The results are expressed as means ± SD. 
4.5 Inflammatory markers 
Current research has suggested immune function alterations in individuals 
with PTSD, but the nature of these alterations is not well understood. Most studies 
report that PTSD is associated with excessive inflammation, characterized by 
increased plasma levels of pro-inflammatory cytokines. However, unaltered 
inflammatory state and even decreased circulatory levels of inflammatory markers 
were also found in association with PTSD. There is also a proposal that excessive 
inflammation is, at least in part, due to insufficient immunosuppression by cortisol. 
In order to examine the inflammatory status of trauma-exposed individuals with 
current PTSD, with life-time PTSD and without PTSD, in this study we analyzed 
general inflammatory markers, such as plasma level of CRP, leukocyte count in 
peripheral circulation and erythrocytes sedimentation rate, as well as plasma 
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levels of multiple cytokines: TNF-α, IL-6, IL-12p70, IL-2, IL-8, IL-5, IL-4, IFN-γ and 
IL-10. One of the examined cytokines, IL-10, is anti-inflammatory cytokine, while 
the others are pro-inflammatory, or the cytokines with both pro- and 
anti-inflammatory actions. 
Determination of general inflammatory markers demonstrated no significant 
differences between current PTSD, life-time PTSD, trauma control and healthy 
control groups, the statistical parameters being as follows: CRP – ANOVA, F = 2.1, 
p = 0.105; number of leukocytes – ANOVA, F = 0.9, p = 0.420; sedimentation – 
ANOVA, F = 8.48, p = 0.978 (Table 4.3). However, these results coincide with 
general suppression of proinflammatory cytokines observed in current PTSD, life-















(n=33)   
 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD F P 
CRP 1.69 ± 1.46 2.27 ± 2.20 3.57 ± 5.42 3.43 ± 3.94 2.09 0.105 
Leukocytes 6.9 ± 1.8 7.2 ± 1.7 7.6 ± 2.2 7.1 ± 1.9 0.95 0.420 
Sediment. 8.2 ± 4.7 7.9 ± 6.2 7.9 ± 7.2 8.5 ± 7.5 0.07 0.978 
TNF-α     89.6 ± 78.0a, b      41.1 ± 44.8a, c  83.8 ± 64.7a       140.3 ± 67.6 12.47 <0.001 
IL-6  115.3 ± 145.0a   95.9 ± 88.3a  113.1 ± 119.6a 221.7 ± 132.2 7.21 <0.001 
IL-12p70  121.4 ± 98.8a, b      47.6 ± 70.7a, c  123.2 ± 100.7a  201.2 ± 115.5 12.82 <0.001 
IL-2     344.2 ± 234.9a, b       202.5±211.9a, c  400.8 ± 226.7a   566.4 ±  131.5 16.04 <0.001 
IL-8     84.8 ± 90.0a, b     20.1 ±  33.1a  63.1 ±  51.9a 128.8 ±  76.8 13.93 <0.001 
IL-5  422.9 ± 393.7a            213 ±313.43a, c 493.2 ± 392.2 690.4 ± 353.5 9.44 <0.001 
IL-4 302.6  ± 175.2a     188.1 ± 201.1a 334.1 ± 200.6 436.3 ± 196.6 8.90 <0.001 
IFN-γ 89.4 ± 73.8     75.2 ± 66.5a 92.4 ± 57.6        126.5 ± 63.2 3.56 0.016 
IL-10 96.6 ± 89.2a   100.2 ± 94.3a         126.2  ±  90.8 167.3  ±  95.0 4.06 0.009 
a significantly different from healthy controls, p< 0.05 
 b significantly different from life-time PTSD, p< 0.05 




TNF-α is a cytokine involved in systemic inflammation and its primary role is 
to partake in the regulation of immune cells. We found that the plasma levels of 
TNF-α significantly differ between the study groups (ANOVA, F = 12.47, 
p < 0.0001) (Table 4.3). As presented in Figure 4.14, significantly lower level of 
TNF-α was registered in the three groups of trauma-exposed subjects in 
comparison to healthy controls. Besides, the level of this cytokine was significantly 
lower in life-time PTSD group than in current PTSD and trauma control groups. 
Figure 4.14. Plasma level of TNF-α. The level of TNF-α was determined using 
multiplex ELISA kit according to the manufacturer’s instructions. The results are 
expressed as the group means ± SD. 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 
p = 0.059 
p = 0.021 
p < 0.000 
p = 0.004 




One of the most important mediators of fever and acute phase response, IL-6 
is also produced by T cells and macrophages in response to trauma and infection. 
Both pro- and anti-inflammatory actions can be attributed to this cytokine. In our 
study, it appeared that war trauma led to diminishment of IL-6 plasma level, as all 
three groups of traumatized subjects displayed significantly decreased IL-6 plasma 
levels than healthy controls (ANOVA, F = 7.21, p < 0.0001) (Table 4.3, Figure 
4.15). 
Figure 4.15. Plasma level of IL-6. The level of IL-6 was determined using 
multiplex ELISA kit according to the manufacturer’s instructions. The results are 
expressed as the group means ± SD. 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 
p < 0.000 
p = 0.003 




IL-12 or IL-12p70 serves to stimulate T cells growth and differentiation and 
is secreted from dendritic cells and macrophages in response to antigenic 
stimulation. Our results have shown that its blood plasma level was lower in 
war-traumatized individuals irrespective of the presence/absence of current or 
life-time PTSD symptoms in comparison to healthy controls, as well as in life-time 
PTSD subjects in comparison to both current PTSD patients and traumatized 
subjects without PTSD (ANOVA, F = 12.82, p < 0.0001) (Table 4.3, Figure 4.16). 
Therefore, the pattern of IL-12 plasma level between the study groups closely 
resembles that of TNFα. 
Figure 4.16. Plasma level of IL-12p70γ. The level of IL-12p70 was determined 
using multiplex ELISA kit according to the manufacturer’s instructions. The 
results are expressed as the group means ± SD. 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 
p = 0.017 
p = 0.023 
p < 0.000 




IL-2 regulates the immune functions of white blood cells in natural response 
to microbial infection and in discriminating between “self” and “non-self”. It is also 
necessary for growth, proliferation and differentiation of T cells. The pattern of its 
plasma level between the groups in our study appeared to be very similar to those 
of TNF-α and IL-6. Its level was significantly lower in traumatized subjects with 
and without PTSD than in healthy controls, and among the three traumatized 
groups the life-time PTSD group displayed the lowest level of this cytokine 
(ANOVA, F = 16.04, p < 0.0001)(Table 4.3, Figure 4.17). 
Figure 4.17. Plasma level of IL-2. The level of IL-2 was determined using 
multiplex ELISA kit according to the manufacturer’s instructions. The results are 
expressed as the group means ±SD. 
 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 
p = 0.001 
p = 0.040 
p < 0.000 
p = 0.013 




IL-8 is known as a neutrophil chemotactic factor and also as a potent 
promoter of angiogenesis. According to the result of our study, a decrees of the 
plasma level of this cytokine can be ascribed to traumatic experiences, since all 
traumatized groups (current PTSD, life-time PTSD and trauma controls) showed 
lower IL-8 level than healthy controls (ANOVA, F = 13.93, p < 0.0001). This 
cytokine is also less abundant in the blood plasma of life-time PTSD patients in 
comparison to both current PTSD patients and trauma controls, thus showing a 
pattern very similar to TNF-α, IL-6 and IL-2 (Table 4.3, Figure 4.18). 
Figure 4.18. Plasma level of IL-8. The level of IL-8 was determined using 
multiplex ELISA kit according to the manufacturer’s instructions. The results are 
expressed as the group means ± SD. 
 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 
p = 0.002 
p < 0.000 
p = 0.001 




Produced by T helper cells and mast cells, IL-5 stimulates B cell growth, 
immunoglobulin secretion and eosinophil activation. In our study, its plasma level 
has been shown to depend on the presence of past or present PTSD symptoms, as 
both PTSD groups (current and life-time) express significantly lower plasma levels 
of this cytokine in comparison to healthy controls (ANOVA, F = 9.44, p < 0.0001). Of 
note, IL-5 level has also been significantly lesser in life-time PTSD patients than in 
traumatized non-PTSD subjects (Table 4.3, Figure 4.19). 
Figure 4.19. Plasma level of IL-5. The level of IL-5 was determined using multiplex 
ELISA kit according to the manufacturer’s instructions. The results are expressed as 
the group means ± SD. 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 
p < 0.000 
p = 0.015 




Among many roles of IL-4, the most prominent are stimulation of T helper 
cells and B cells differentiation, as well as T-cell and B-cell proliferation. Its pattern 
of abundance in the blood plasma between our study groups closely resembles 
that of IL-5: IL-4 plasma level reflects vulnerability to PTSD, as it is lower in both 
groups vulnerable to PTSD in comparison to the controls, and it is also lower in 
lifetime PTSD subjects than in trauma controls (ANOVA, F = 8.90, 
p < 0.0001)(Table 4.3, Figure 4.20). 
Figure 4.20. Plasma level of IL-4. The level of IL-4 was determined using 
multiplex ELISA kit according to the manufacturer’s instructions. The results are 
expressed as the group means ± SD. 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 
p < 0.000 
p = 0.019 




Immunostimulatory and immunomodulatory roles of IFN-γ are of an utmost 
importance for both innate and adaptive immunity. Its antiviral, 
immunoregulatory and anti-tumor actions are numerous. In our study, it has 
exhibited a unique pattern of plasma level between the study groups (Table 4.3, 
Figure 4.21): the only statistically significant between-group difference was a 
decrease of IFN-γ level in life-time PTSD subjects in comparison to healthy controls 
(ANOVA, F = 3.56, p = 0.016). This result implies that the level of IFN-γ might be 
associated with remission of PTSD. 
Figure 4.21. Plasma level of IFN-γ. The level of IFN-γ was determined using 
multiplex ELISA kit according to the manufacturer’s instructions. The results are 
expressed as the group means ±SD. 
p = 0.013 
   Current            Life-time             Trauma             Healthy 




Among the cytokines analyzed in this study, IL-10 was the only 
anti-inflammatory cytokine, counteracting the hyperactive immune response. This 
cytokine acts as human cytokine synthesis inhibitory factor and besides, exerts 
pleiotropic effects in immunoregulation and inflammation. Between-group 
differences in its blood plasma level, observed in our study, suggest that the level 
of this cytokine might be associated with vulnerability to PTSD. Namely, the 
individuals presenting both current or past PTSD symptoms had lower IL-10 
plasma levels than healthy controls (ANOVA, F = 4.06, p = 0.009)(Table 4.3, 
Figure 4.22) 
Figure 4.22. Plasma level of IL-10. The level of IL-10 was determined using 
multiplex ELISA kit according to the manufacturer’s instructions. The results are 
expressed as the group means ± SD. 
p = 0.024 
   Current            Life-time             Trauma             Healthy 
     PTSD                PTSD               controls            controls 





5.1 Plasma cortisol level and HPA axis sensitivity 
Proper negative feedback regulation of HPA axis exerted by cortisol appears 
to be critical for a healthy stress response. Profound alterations in the regulation of 
this system have been implicated in the pathogenesis of stress-related psychiatric 
disorders, such as PTSD (Yehuda, 2006). Numerous  studies on cortisol signaling 
abnormalities in PTSD, however, yielded heterogeneous results, so that the exact 
role of cortisol and HPA axis in the pathogenesis and maintenance of this disorder 
is still a matter of debate. Some authors reported lower basal cortisol levels in the 
blood plasma, urine or saliva from PTSD patients as compared to control subjects 
(Yehuda et al., 1990; Yehuda et al., 1995b; Boscarino, 1996; Yehuda et al., 1996; 
Heim et al., 1998; Glover & Poland, 2002; Yehuda, 2002a; Wessa et al., 2006), some 
reported the opposite data (Pitman & Orr, 1990; Lemieux & Coe, 1995; Liberzon et 
al., 1999; Lindley et al., 2004), while some found no differences (Baker et al., 1999; 
Atmaca et al., 2002; Eckart et al., 2009). These discrepancies “indicate that there is 
not a one-to-one correspondence between cortisol output and PTSD diagnosis” as 
Rasmusson et al. (2003) conclude in their review on neuroendocrinology of PTSD. 
In an excellent meta-analysis, Meewisse et al. (2007) came to the same conclusion. 
Both these groups of researchers found that only a part of the variability of 
published results can be accounted for by methodological differences. Additional 
sources of variability may include various factors, such as comorbid depression, 
current versus life-time PTSD, severity of PTSD symptoms, time elapsed from the 
traumatic event, duration of trauma exposure, and whether or not control groups 
have a history of trauma (Meewisse et al., 2007). 
In our present study we measured plasma cortisol level in a relatively large 
cohort of only-male subjects divided into four groups in a way that allowed us to 
relate the cortisol level to trauma exposure, PTSD symptoms, resilience to PTSD, 




differences in the basal cortisol level, represented as the mean of thirteen 
nocturnal measurements encompassing the period from 22:00 p.m. to 9 a.m. and 
performed in the clinical setting. Considering the sample size, accuracy of subject 
classification, the applied methodology and precise matching of the study groups 
by a number of parameters (gender, age, type of trauma, educational level, body 
mass index, lifestyle habits, etc.), it can be concluded that basal cortisol level 
alterations cannot be associated with trauma exposure, current or life-time PTSD 
symptoms, resilience to PTSD, vulnerability to PTSD and remission of the disorder. 
A recent study by Savic et al. (2012) shows that the apparent connections between 
cortisol and PTSD are actually realized via personality traits, which might explain 
the heterogeneity of findings on basal cortisol levels in traumatized individuals 
with or without PTSD. This study demonstrated that the mediating role between 
cortisol level and PTSD can be ascribed to personality traits, since basal cortisol 
level was shown to be related to PTSD only indirectly, inasmuch as low 
Conscientiousness (one of the „Big Five“ personality traits) is related to this 
psychopathology. 
Patients with PTSD have been found to display blunted cortisol awakening 
response i.e. lesser cortisol “spike” upon awakening and higher circulating 
concentrations of cortisol in the evening (Wessa et al., 2006). Interestingly, 
flattening of the daily cortisol rhythm has been associated with a number of 
chronic medical illnesses including cardiovascular disease and insulin resistance, 
as well as other psychiatric disorders including major depression and chronic 
fatigue syndrome (Nater et al., 2008).  
The cortisol level is thought to be a good measure of HPA axis activity, since 
cortisol is the final product of this axis. However, not only the activity, but also the 
regulation of HPA axis activity, should be taken into consideration as an important 
biological correlate of PTSD and any other psychiatric disorder related to stress. 
Hence, in a number of studies the challenge paradigms, such as DST and combined 
DEX/CRH test, were employed in order to evaluate the sensitivity of HPA axis to 
suppression by cortisol. Again, different studies provided rather inconsistent data. 




to healthy controls (Thaller et al., 1999; Atmaca et al., 2002), some reported no 
inter-group differences (Vythilingam et al., 2010), but most found that PTSD is 
characterized by hyperresponsiveness of HPA axis to cortisol feedback (Yehuda et al., 
1995a; Rinne et al., 2002; Grossman et al., 2003; Newport et al., 2004; Yehuda et 
al., 2004c; Lange et al., 2005). A review of DST studies in PTSD is given in de Kloet 
et al. (2006). The key finding of these studies was that PTSD patients in comparison 
to control subjects display lower plasma cortisol level after administration of 
0.5 mg dexamethasone dose, which was interpreted as a hypersensitive (or 
disease-sensitized) cortisol feedback (Yehuda et al., 2004b) and afterwards 
considered as a hallmark of PTSD pathophysiology. The results of our study 
demonstrate that dexamethasone applied at a low dose of 0.5 mg leads to 
increased suppression of HPA axis activity in PTSD patients with current or past 
symptoms in comparison to healthy controls, which is reflected in the lower ratio 
between post-dexamethasone and pre-dexamethasone plasma cortisol levels in 
PTSD than in healthy subjects. These results confirm previous observations that 
PTSD is associated with hyperresponsiveness of HPA axis. Moreover, combined 
with the data that basal cortisol level is not changed in association with the 
disorder, our data on PTSD-sensitized HPA axis imply that there is a disagreement 
between indicators of HPA axis activity in central versus peripheral components of 
this axis. Namely, when DST indicates hyperresponsiveness of pituitary and 
hypothalamus to dexamethasone, one should expect decreased activity of HPA axis 
and, hence, a decreased level of plasma cortisol. Since it was not the case in our 
study, we suppose that adrenal glands are either downregulated by a so called 
“ultra short” glucocorticoid negative feedback, or insensitive to the increased 
activity of stress response systems in the brain. Therefore, our data open new 
questions regarding the regulation of cortisol secretion in adrenal glands in 
traumatized individuals with and without PTSD. These questions might be 
answered by detailed inspection of GR and ACTH receptors expression and activity 
in the cortex of adrenal glands. 
In most previous studies on the relation between PTSD and HPA axis 




traumas than trauma controls was not taken into account (e.g. Yehuda et al., 
1995a; Newport et al., 2004; Yehuda et al., 2004a). Interestingly, the level of 
traumatization appeared to be an important confounding factor. A recent study of 
Savic et al. (2012) has shown that significant differences on the low dose DST 
between PTSD patients and trauma controls are not actually related to PTSD 
pathology, but to the level of war-related trauma exposure. Besides, Savic et al. 
(2012) suggested that even though war-related traumatic events are not of the 
same degree of distress, the factor influencing HPA axis sensitivity to cortisol 
feedback is the number of traumatic experiences rather than their intensity. This 
led to a conclusion that the repetition and not the degree of activation of the HPA 
axis plays a role in sensitizing its regulatory function.  
5.2 Corticosteroid receptors expression in the 
lymphocytes 
The observation that PTSD is associated with increased HPA axis sensitivity 
to cortisol has brought the GR into the focus of the research, since cortisol exerts 
its cellular effects through the GR. GR is a hormone-inducible transcription 
regulator belonging to the superfamily of nuclear receptors. It is a ubiquitous 
cytoplasmic protein, present in almost all human tissues, where it mediates 
various cellular responses to cortisol. It specifically binds cortisol and upon 
hormone binding translocates from the cytoplasm to the nucleus where it 
regulates transcription of glucocorticoid target genes. GR can activate gene 
transcription by direct binding to specific regulatory DNA sequences called 
glucocorticoid-responsive elements (GREs). A consensus GRE is the 
pentadecameric imperfect palindrome (Nordeen et al., 1990) and the receptor 
binds to it in the form of dimer  (La Baer & Yamamoto, 1994). The response of 
many genes to glucocorticoids depends not only on GR binding to the GRE, but 
additionally requires the binding of other transcription factors to adjacent binding 
sites (Schoneveld et al., 2004a), which is a way of integrating multiple signal inputs 




GR are referred to as negative GREs (nGREs) (Truss & Beato, 1993). In the case of 
certain genes, including the genes encoding cytokines, GR does not bind directly to 
the DNA to exert its transcriptional effect, but is recruited to DNA-bound 
transcription factors, such as NFκB and AP-1 in a regulatory complex, a mechanism 
known as tethering (Schoneveld et al., 2004b). 
The investigations of expression and functional properties of GR in PBMCs 
from PTSD patients have yielded inconsistent results. The number of 
glucocorticoid binding sites (Bmax) in PBMCs from PTSD patients has been reported 
to be increased (Yehuda et al., 1991; Yehuda et al., 1995a), decreased (de Kloet et 
al., 2007) and unchanged (Wheler et al., 2006; Shalev et al., 2008) in comparison 
with control individuals. The level of the GR protein in different lymphocyte 
subpopulations, measured by flow cytometry,  was found to be lower in PTSD 
patients than in the controls in one study (Gotovac et al., 2003) and unchanged in 
the other (Vidovic et al., 2007). In addition, the evidence has been provided for 
both decreased (Su et al., 2009) and unchanged (van Zuiden et al., 2011a) 
PTSD-related level of GR gene expression evaluated by quantitative PCR. 
In the present study we had at least two reasons to examine PTSD- and war 
trauma-related alterations in the GR level of expression in PBMCs. The first 
includes the inconsistency of the existing literature data, and the second derives 
from our result that basal cortisol level in the four study groups was rather 
uniform, while the responsiveness of HPA axis to cortisol was increased in the 
current PTSD group. One of the possible explanations for these results might be 
found in the level of expression of the GR, as an increased level of GR protein in 
PTSD patients compared to non-PTSD subjects might be responsible for increased 
responsiveness of HPA axis to cortisol, despite unchanged plasma level of the 
hormone. Therefore, we sought to determine relative GR protein level and for that 
purpose we applied a semi-quantitative Western blot approach and used PBMCs, 
among which the lymphocytes predominate. In order to learn whether  GR protein 
level may be a biological correlate of PTSD pathology and war trauma exposure, or 




trauma survivors with current PTSD, with life-time PTSD and without PTSD, as 
well as non-traumatized healthy controls.  
Examining the GR protein level in the lymphocytes, we detected two 
immuno-specific bands, one of which corresponded to molecular mass of the GRα 
isoform (97 kDa), while the other had higher molecular mass. It is known that GR 
is subject to mono- and polysumoylation (Le Drean et al., 2002), which regulates 
the stability of the receptor protein and influences its transcriptional activity 
(Holmstrom et al., 2003). GR has three attachment sites for SUMO-1, which does 
not form polymeric chains (Tian et al., 2002). It seems that GR is also susceptible to 
monoubiquitination which also affects its transactivation activity (Ismaili et al., 
2005). Assuming that the slower migrating band detected in our experiments 
represents the GR monosumoylated by SUMO-1 or monoubiquitinated, and taking 
into account that the appearance and the abundance of both bands exhibited a 
rather uniform pattern among the study groups, it could be supposed that the rate 
of GR monosumoylation or monoubiquitination is not related to trauma exposure, 
PTSD symptoms or resilience to PTSD. Besides, comparison of the intensities of the 
two GR bands within the whole sample, as well as within the study groups 
separately, suggested a redistribution of the receptor between the two isoforms, 
which is an expectable consequence of the presumed modification(s). 
An important result of these experiments was that current PTSD patients in 
comparison to trauma controls, displayed elevated GR protein level in PBMCs, 
suggesting that increased GR expression should be considered as a factor 
underpinning the observed increased sensitivity of HPA axis to cortisol. However, 
all human studies on HPA axis activity, including the ours, suffer from a limitation 
that, because of inaccessibility of human brain tissues and pituitary, the 
conclusions have to be drawn out of the experiments done on available human 
cells, most frequently PBMCs. These, easily accessible immune cells, express high 
levels of GR and represent targets for GR anti-inflammatory and 
immunosuppressive actions. As such, they can be exploited as a very useful model 
for basic studies concerning immunological aspects of PTSD pathophysiology, as 




alterations as potential preexisting vulnerability/resilience factors, or correlates of 
PTSD or trauma. Besides, it has been shown that gene expression changes in 
PBMCs reflect various pathological states (Tang et al., 2001), including PTSD and 
other psychiatric disorders (Segman et al., 2005; Tsuang et al., 2005; Zieker et al., 
2007; Su et al., 2009; Yehuda et al., 2009), and in some instances are paralleled by 
changes in neural tissue (Sullivan et al., 2006; van Heerden et al., 2009). These are 
arguments in favor of the use of these cells even in basic research on 
neuroendocrine and cognitive aspects of PTSD pathophysiology (Gladkevich et al., 
2004). 
In the brain structures controlling HPA axis activity, cortisol operates via two 
types of receptors: mineralocorticoid receptor (MR) and GR. MR is predominantly 
expressed in the limbic structures, binds cortisol with high affinity and is 
substantially occupied throughout the ultradian and circadian cycle. The lower 
affinity GR is widely distributed and becomes occupied only at cortisol peaks and 
after stress. While the MR is primarily responsible for integrity and stability of the 
stress circuitry, the GR is implicated in termination of the stress response, recovery 
from stressful challenge and facilitation of behavioural adaptation in preparation 
for future challenges. Therefore, the balance between MR- and GR-mediated 
actions is considered crucial for proper processing of stressful information, while 
the imbalance may contribute to increased vulnerability to stress-related mental 
disorders (De Kloet et al., 1998; Oitzl et al., 2010; Harris et al., 2012; ter Horst et al., 
2012). So far the studies on corticosteroid receptor alterations accompanying 
PTSD and trauma were focused mainly on GR (Yehuda, 2009) and, to our 
knowledge, there are only two papers examining MR function in PTSD patients 
(Kellner et al., 2002; Otte et al., 2006). Both papers reported no alterations in 
MR-mediated HPA axis regulation related to PTSD. However, Wellhoener et al. 
(2004) evidenced a rise of both basal and stress-induced cortisol levels in healthy 
humans upon MR blockade, and some animal studies demonstrated an increase in 
hippocampal MR density after psychological stress (Gesing et al., 2001; Muller et 
al., 2003; Ladd et al., 2004). These studies provided the basis for a proposal that, in 




It is well known that cortisol exerts immunosuppressive and 
anti-inflammatory effects and there is a growing body of evidence that PTSD 
pathogenesis is connected with alterations in inflammatory functions of the 
immune system. Therefore, cortisol and GR became a focus of PTSD research not 
only because of the implication in HPA axis regulation, but also because of 
immunomodulatory actions. Measurements of the production of cytokines in the 
presence of GR or MR antagonists have led to the conclusion that cortisol exerts its 
immunomodulatory effects not only via GR, but via both corticosteroid receptors, 
GR and MR, which act synergistically to mediate suppression of proinflammatory 
responses (Sauer et al., 1996; Dimitrov et al., 2004). Since both GR and MR operate 
at neuroendocrine-immune interface, in order to better understand the role of 
these receptors in PTSD pathophysiology and to unravel their possible 
contribution to inter-individual differences in coping with stress, it is necessary to 
examine the level of expression of both the receptors, functional status and 
molecular interactions in the central nervous system, as well as in the peripheral 
tissues. 
Since PBMCs express both GR and MR it might be expected that disbalance in 
the expression levels of the two receptors may affect the immunosuppressive 
actions of glucocorticoids in these cells. However, the data from the present study 
show that the level of MR protein was similar in all four groups of participants and, 
combined with the GR data, indicate that the lymphocyte MR/GR ratio was not 
altered regardless of traumatic experiences and presence of past or current PTSD 
symptoms. Knowing that the level of corticosteroid receptors expression is only 
one among numerous determinants of the sensitivity of a target cell to cortisol, this 
observation suggests that differences in cortisol signaling between traumatized 
individuals with or without PTSD and non-traumatized healthy controls should be 
searched for among other regulatory mechanisms, such as those regulating the 
receptors cytoplasmic/nuclear shuttling, covalent modifications and 
transactivation activity. A key role in regulating these important steps of cortisol 
action belongs to chaperones (Hsp90 and Hsp70) and co-chaperones bound to the 




5.3 Heat shock proteins 
5.3.1 Intracellular heat shock proteins 
GR and MR act as ligand-activated transcription regulators that, when 
unliganded, predominantly reside in the cytoplasm of target cells within 
Hsp90-based chaperone complexes, the components of which are HSPs Hsp90 and 
Hsp70, co-chaperones and immunophilins (Pratt & Toft, 1997a). Hsp70 recognizes 
newly synthesized receptors, and is required for their initial folding, while Hsp90 
regulates maturation of the receptors’ high-affinity hormone-binding conformation 
and maintains unliganded receptors in transcriptionally inactive state by keeping 
them in a form incapable of DNA binding (Galigniana et al., 2004; Grad & Picard, 
2007). Hsp90 also controls intracellular trafficking, nuclear retention, 
transcriptional activity (Galigniana et al., 2010), as well as proteolytic degradation 
of the receptors (Siriani et al., 2005). Therefore, the interaction of corticosteroid 
receptors with Hsp90 and Hsp70 represents an important determinant of target 
tissue sensitivity to corticosteroid hormones (Pratt & Toft, 1997a; Galigniana et al., 
2004; Grad & Picard, 2007; Galigniana et al., 2012).   
HSPs are essential components of the cellular stress response. Their 
synthesis can be induced in virtually all cells by diverse physiological and 
environmental stressful factors (Richter et al., 2010). Even the pure psychological 
stressors have been shown to increase both intracellular and circulating levels of 
HSPs (Lewthwaite et al., 2002; Fleshner et al., 2004). These proteins are thought to 
serve functions beneficial for cell survival in various stress-related disorders, 
possibly including PTSD (Zhang et al., 2010) and considering their role in 
chaperoning corticosteroid receptors, it can be expected that changes in their 
intracellular concentrations may affect cellular responsiveness to cortisol. This 
was the reason why we examined the level of expression of Hsp90 and Hsp70 in 
PBMCs from war trauma-exposed individuals with current PTSD, life-time PTSD 
and without PTSD, as well as from non-traumatized healthy controls. Furtheron, 




and the HSPs expression, as well as the relationship between the level of 
expression of the studied proteins to trauma exposure, PTSD symptoms, 
vulnerability or resilience to PTSD and remission of the disorder. 
Current study provides evidence that the level of Hsp90 and Hsp70 
expression in PBMCs do not differ between men with current PTSD, life-time PTSD 
and without PTSD as compared to non-traumatized healthy individuals. Besides, 
the data reveal that the two corticosteroid receptors (MR and GR) expression 
levels are differently correlated with the levels of Hsp90 and Hsp70. Some of these 
associations have been shown to be weakened when accompanied by PTSD 
symptoms, while some were influenced by war trauma exposure. 
Induction of HSPs is known to be a part of the generalized stress response 
that serves to protect cells against cytotoxic stimuli (Richter et al., 2010), including 
cytokine toxicity (Bocci, 1988; Barone et al., 1997). It is also known that trauma 
exposure and PTSD are accompanied by increased production of proinflammatory 
cytokines (Kawamura et al., 2001; Rohleder et al., 2004; Gill et al., 2008; Gill et al., 
2010).  Our data, however, show that lymphocyte Hsp90 and Hsp70 expression 
levels in war trauma-exposed men with and without PTSD are similar to the levels 
in non-traumatized healthy controls. We suppose that one of possible explanations 
of this finding might be the long time elapsed between trauma exposure and 
recruitment for the study. Namely, HSPs induction might serve to restrain the 
proinflammatory response and, thus, protect cells from cytokine toxicity only in 
the early aftermath of trauma. Recently, Sriram et al. (2012) have formulated a 
mathematical model of Hsp90 dynamics in animals exposed to acute and chronic 
stress, and hypothesized that the model can be extended to psychiatric disorders 
such as PTSD. The model predicts low levels of Hsp90 upon high levels of stress, 
and our data are probably the first experimental data corroborating this 
prediction. 
Interestingly, our data suggest that the concentrations of corticosteroid 
receptors are correlated with that of HSPs, and that the two receptors differ in 
regard to their relationship with Hsp70. On the basis of the data showing that heat 




2004) and inversely, that glucocorticoids can attenuate the heat shock response by 
preventing HSF1 recruitment to the promoters of heat shock genes (Wadekar et al., 
2004), Sanchez and coworkers proposed a reciprocal mechanism regulating GR 
and HSF1 signaling (Jones et al., 2004). It is tempting to speculate that the 
proposed complex functional relationship between GR and HSF1 may underlie the 
observed correlation between GR and Hsp90 expression levels. 
The Hsp90-based chaperone heterocomplexes of corticosteroid receptors 
include one of the two Hsp90-binding immunophilin co-chaperones, FKBP51 or 
FKBP52, the functional exchange of which has been demonstrated for both GR 
(Davies et al., 2002) and MR (Gallo et al., 2007). FKBP52 is regarded as a positive 
regulator of GR, but does not affect the functions of MR, while FKBP51 impairs 
nuclear localization of both the receptors (Wochnik et al., 2005; Gallo et al., 2007). 
Besides, FKBP51 expression is induced by glucocorticoids as a part of an 
intracellular ultra-short feedback loop regulating GR activity (Vermeer et al., 
2003). Functional and genetic variations of FKBP51 are thought to be a major risk 
factor for development of PTSD (Binder et al., 2008; Xie et al., 2010). The fact that 
FKBP51 and FKBP52 are Hsp90 co-chaperones associated with both corticosteroid 
receptors, may explain our finding that both GR and MR expression levels correlate 
with Hsp90 level. 
On the other hand, the differences between GR and MR in respect to their 
correlation with Hsp70 may stem from a dissimilar interaction of the two 
receptors with Bag-1, a co-chaperone of Hsp70, which has been reported to inhibit 
DNA-binding and transactivation functions of GR in an isoform-specific manner, 
while leaving the activity of MR unaffected (Schneikert et al., 1999; Crocoll et al., 
2000). Further investigation is necessary in order to learn whether different 
functional relationships of GR and MR with this Hsp70 co-chaperone may result in 
different relations between the two receptors expression levels with the level of 
Hsp70. 
The results of the present study demonstrate that the association of GR and 
Hsp90 expression levels was affected by exposure to war trauma, since the 




from the three trauma-exposed groups of participants were significantly higher 
than in the group of non-traumatized healthy controls. The correlation between 
MR and Hsp70 concentrations, on the other hand, was found to depend on the 
presence of PTSD symptoms, since the correlation coefficient in the current PTSD 
group was significantly lower in comparison to that in the trauma control group. 
These results imply that war trauma and symptoms of PTSD may affect the 
relations between GR and MR expression levels, on one hand, and Hsp90 and 
Hsp70 levels, on the other, without affecting the expression levels of the studied 
proteins, the GR being the only exception (Matić et al., 2013). The changes in these 
relations may reflect the changes in the interactions of the corticosteroid receptors 
with the HSP chaperones. Knowing that corticosteroid receptor heterocomplexes 
are dynamic structures, the composition of which changes under different 
conditions (Edwards et al., 1992; Čvoro et al., 1998; Brkljačić et al., 2004) and that 
chaperones are important factors controlling the activity of corticosteroid 
receptors (Pratt & Toft, 1997a; Galigniana et al., 2004; Grad & Picard, 2007; 
Galigniana et al., 2010), one can propose that changes of these interactions would, 
consequently, lead to alterations of the receptors functional activity. 
The notable strengths of the current study include relatively large sample 
size, the uniformity of the study groups in respect to gender, age, ethnicity, types of 
experienced traumatic events and educational level, as well as the detailed 
assessment of PTSD and precise classification of the participants into the four 
groups by experienced specialists. These advantages, encourage us to propose that 
the results presented herein provide reliable arguments that further research 
regarding the role of corticosteroid receptors in pathogenesis of PTSD should be 
focused at the interaction of these receptors with their chaperones and 
co-chaperones.  
5.3.2 Extracellular heat shock proteins 
PTSD is not a normative response to extreme stressors, since only a subset of 




reason why PTSD has recently been reconceptualized as a disorder of stress 
response systems – HPA and SAM axes, leading to maladaptive responses and a 
failure to cope with the stressor (Yehuda, 2009). Based on such a concept and 
given that neuroendocrine systems are known to regulate immune functions, it is 
reasonable to predict that patients with PTSD may show immune changes. Namely,  
both glucocorticoids and catecholamines exert powerful effects on the immune 
system, explaining numerous findings that suggested changes in inflammatory 
function of the immune system in patients with PTSD. Moreover, these patients are 
known to have increased rates of comorbidity with somatic disorders that involve 
immune and inflammatory processes. Therefore, it is of interest to explore possible 
mechanisms by which changes of the neuroendocrine system may be related to 
immune alterations and medical comorbidities of PTSD. 
On the basis of the data demonstrating low levels of cortisol and high levels 
of inflammatory markers in association with PTSD, it has been hypothesized that 
excessive inflammation in individuals with PTSD might be a consequence of 
insufficient immunosuppression by cortisol. However, the data on cortisol levels 
and cortisol receptor functioning in PTSD patients are inconsistent, and most 
studies, including our own, have not presented evidence for cortisol decline 
(Meewisse et al., 2007) or for its receptor functional impairment (Yehuda et al., 
1995a; Yehuda et al., 2004b; Vidovic et al., 2007) associated with the disorder. 
In the present study we investigated possible role of HSPs in the relationship 
between PTSD and inflammation. We hypothesized that alterations in 
inflammatory status related to trauma and/or PTSD might be a consequence of 
Hsp70 and Hsp60 induction and release by psychological trauma. To test this 
hypothesis, we examined circulatory levels of Hsp70 and Hsp60 in patients with 
current PTSD and with life-time PTSD, in traumatized individuals without PTSD 
and in healthy subjects. 
Until recently, HSPs have mostly been regarded as intracellular molecules 
that mediate a range of essential housekeeping and cytoprotective functions. The 
usual view of eukaryotic HSPs is that they are intracellular molecules that are 




presence in) the extracellular environment indicates non-physiological tissue 
damage and therefore induces a range of proinflammatory responses. Findings 
from several studies are consistent with this idea. Human Hsp60 induces the 
expression of the adhesion molecules E-selectin, ICAM-1 and VCAM-1 on vascular 
endothelial cells, and the secretion of interleukin-6 from vascular endothelial cells, 
smooth muscle cells and macrophages (Kol et al., 1999; Kol et al., 2000). The 
intracellular localization of eukaryotic HSPs in healthy circumstances, the typical 
release of HSPs from infectious agents and the capacity of both human and 
bacterial HSPs to elicit innate and adaptive proinflammatory responses seem to be 
consistent with the proposed role for these proteins as links between pathogenic 
processes involving necrotic cell death, and the induction of innate and adaptive 
immunity. 
However, further evidence suggests an alternative to this point of view. 
Interest in the role of HSPs as intercellular signalling molecules has been fuelled by 
the observations that these molecules can be released and are present in the 
extracellular environment under physiological conditions. They can be released 
from some viable (non-necrotic) mammalian cell types, including cultured rat 
embryo cells (Hightower & Guidon, 1989), human islet cells (Child et al., 1995), rat 
glial cells and a human neuroblastoma cell line (Bassan et al., 1998) and cultured 
vascular smooth muscle cells exposed to oxidative stress (Liao et al., 2000). These 
findings have profound implications for the perceived role of these proteins as 
exclusively proinflammatory intercellular signalling molecules and danger signals. 
They can elicit cytokine production and adhesion molecule expression in a range of 
cell types, and they can deliver maturation signals and peptides to antigen 
presenting cells through receptor-mediated interactions. These functions suggest 
that HSPs could be immunoregulatory agents with potent and widely-applicable 
therapeutic uses. 
The two HSPs examined in our study, Hsp60 and Hsp70, are present in the 
peripheral circulation of healthy individuals (Pockley et al., 1998; Pockley et al., 
1999; Pockley et al., 2000; Xu et al., 2000; Rea et al., 2001; Lewthwaite et al., 2002; 




are capable of activating pro-inflammatory responses, which can exacerbate 
diseases, such as atherosclerosis (Camici, 2002; Pockley et al., 2003) and coronary 
heart disease (Pockley et al., 2000; Zebrack & Anderson, 2002), but can also act 
beneficially, to facilitate recovery from bacterial infection (Campisi et al., 2002). 
Psychological stressors have been shown to increase both intracellular and 
circulating levels of HSPs (Lewthwaite et al., 2002; Fleshner et al., 2004), thus 
contributing to development of coronary heart disease. Therefore, there was a 
rationale for a belief that eHsp60 and eHsp70 levels might be increased in patients 
with PTSD. 
When we determined plasma levels of constitutive and inducible isoforms of 
Hsp70, as well as the level of Hsp60 in current and life-time PTSD patients, 
traumatized non-PTSD subjects and healthy controls, it was found that the four 
study groups did not differ in regard to plasma levels of the examined HSPs. The 
lack of between-group differences in the plasma level of HSPs might be possibly 
explained by a long time period elapsed between trauma exposure and 
recruitment for the study (minimum 6, maximum 16 years), since HSPs induction 
and release might serve to modulate proinflammatory response only in the early 
aftermath of trauma. Furthermore, serum Hsp60 and Hsp70s levels were not 
correlated with a range of measures including age, number of traumatic events, 
score on CAPS PTSD scale, score on BDI depression scale and markers of 
inflammation, such as CRP, sedimentation and number of leukocytes per ml blood. 
In addition, no associations were found between eHsp60 or eHsp70s and 
cardiovascular risk factors, including body mass index, blood pressure, smoking 
status, body composition, triglycerides, HDL, LDL and total cholesterol, blood 
glucose and insulin concentration, HOMA index and plasma leptin level. 
Interestingly, we did not observe the correlation between the intracellular and 
extracellular levels of Hsp60 or Hsp70s, a result speaking in favor of the possibility 




5.4 Inflammatory markers 
The immune system is well regulated; however, psychological stress can 
exert an excessive demand on regulatory functions, particularly if the stressor is 
excessive or prolonged, resulting in risk for excessive inflammation (Fries et al., 
2005). Indeed, current studies have reported immune function alterations in 
individuals with PTSD, but the data are inconclusive, leading to an insufficient 
understanding of the nature of immune function alterations in PTSD. Some studies 
provided evidence for association of chronic PTSD with excessive inflammation, 
but this finding is not universal and the nature of immune function alterations in 
individuals with PTSD remains to be determined. 
The immune and neuroendocrine systems are closely related. 
Neuroendocrine systems are known to regulate immune function, while, on the 
other hand, immune alterations are thought to play a central role in the 
pathophysiology of neuropsychiatric disorders. Therefore, it is reasonable to 
predict that patients with PTSD may show immune changes and that immune 
system plays a role in the pathophysiology of PTSD and in medical illnesses found 
along with PTSD. Furthermore, because glucocorticoids are well known for their 
antiinflammatory effects, it is reasonable to theorize that reduced circulating 
concentrations of cortisol seen in some patients with PTSD may be responsible for 
increased inflammation in the same individuals. However, studies directly relating 
cortisol and inflammatory markers in PTSD are scarce. Attenuated cortisol 
responses have been associated with enhanced IL-6 and IL-1 beta responses to 
stress in healthy individuals (Kunz-Ebrecht et al., 2003), suggesting that low 
circulating concentrations of cortisol may foster a hyperinflammatory state, 
especially in the context of stress. 
In the present study no alterations in the plasma cortisol level were observed 
in association with trauma-exposure or PTSD, since the basal cortisol level, 
calculated as a mean from thirteen nocturnal measurements, did not differ 
between trauma-exposed men with or without PTSD and corresponding 




between cortisol level and inflammatory status in the four groups of participants, 
we performed determination of general inflammatory markers, such as plasma 
CRP level, erythrocyte sedimentation rate and leukocyte count. No between-group 
differences in these inflammatory parameters were observed, demonstrating that 
general inflammatory status of current and life-time PTSD patients and 
trauma-exposed non-PTSD subjects was indistinguishable from that of 
non-traumatized healthy participants. Furthermore, correlation analyses revealed 
no associations between cortisol level and any of the examined inflamatory 
markers. Since low grade inflammation might not be noticable at the level of 
general inflammatory markers, such as CRP, erythrocyte sedimentation rate and 
leukocyte count, we continued with more detailed studies on inflammatory 
functions of the immune system and more deeply examined the relations between 
cortisol signalling and inflammatory response to trauma. In the present study we 
measured plasma levels of multiple pro-inflammatory and anti-inflammatory 
cytokines in order to unravel possible PTSD- or trauma-related alterations in 
inflammatory functions of the immune system and to correlate various cytokine 
levels with cortisol signaling parameters. 
The results of our study showed the highest plasma levels of all examined 
cytokines in the participants belonging to healthy control group in comparison to 
other study groups, implying that trauma-exposure and PTSD could rather be 
linked to immunosuppression than to enhanced inflammation. Precisely, cytokines 
such as TNF-α, IL-6, IL-12p70, IL-2 and IL-8 were present at significantly lower 
levels in the plasma from the three groups of trauma-exposed subjects (current 
PTSD, life-time PTSD and trauma controls) as compared to healthy controls, 
meaning that the level of these pro-inflammatory cytokines might be connected 
with trauma-exposure rather than with the presence of current or life-time PTSD 
symptoms. On the other hand, the levels of IFN-γ, IL-5, IL-4 and anti-inflammatory 
cytokine IL-10 were significantly lower in current PTSD and life-time PTSD groups 
than in trauma and/or healthy control groups, suggesting that the level of these 
cytokines could be related to PTSD pathology rather than to trauma-exposure. 




level is not associated with the levels of the cytokines. The only exception in the 
healthy control group was IL-12p70, the level of which was significantly correlated 
with basal cortisol level. In the current PTSD group, basal cortisol level was related 
only to the levels of IL-4 and IL-5, and in the trauma control group it correlated 
with the levels of IL-12p70, IL-8 and IL-6. 
The explanation for the lack of correlation between cytokine and cortisol 
levels might be found in the fact that the actions of hormones can not be 
determined solely as a function of circulating concentrations. Instead, hormone 
effects also depend on tissue sensitivity, which is determined by the corresponding 
receptor number and functional status. PTSD patients have been found to exhibit 
altered glucocorticoid sensitivity in both endocrine tissues and immune cells 
(Yehuda et al., 2004b; Yehuda et al., 2004c; de Kloet et al., 2007). In addition, some 
studies suggest that GR number per cell may be increased in immune cells (Yehuda 
et al., 1991; Yehuda, 2009) and our present study shows that current and life-time 
PTSD patients, in comparison to trauma controls, display an increased level of GR 
expression in peripheral lymphocytes. Assuming that patients with PTSD exhibit 
enhanced glucocorticoid sensitivity, both in the central nervous system and in 
peripheral (immune) tissues, it can be expected that they should have ‘‘normal” 
concentrations of circulating inflammatory markers, even when cortisol level is 
low. One may even predict that patients with PTSD would have even reduced 
inflammatory markers, as observed in our study. 
Nevertheless, multiple studies suggest that PTSD involves enhanced 
inflammatory activation. How can this apparent paradox be explained? First, it is 
possible that enhanced inflammation in patients with PTSD may not be the direct 
result of low circulating concentrations of cortisol. Instead, increased inflammation 
may be driven by enhanced SAM system activity found in PTSD patients. Increased 
sympathetic activity in patients with PTSD could be secondary to reduced cortisol, 
especially in the context of stress challenge (Yehuda, 2009). Increased SAM system 
activity may then enhance the activity of inflammatory pathways, including NF-κB 
(Bierhaus et al., 2003). With this possibility, low circulating concentrations of 




Second, it also may be possible that the low circulating concentrations of cortisol 
found in a portion of patients with PTSD may fall below critical thresholds needed 
to maintain normal inflammatory function, even in the presence of enhanced 
glucocorticoid sensitivity. If this hypothesis is correct, inflammatory excess in 
these patients should respond rapidly to glucocorticoid therapy without altering 
SAM system activity. It is also important to point out that inflammatory alterations 
in patients with PTSD may develop independently of cortisol levels, a possibility 
corroborated by our findings that plasma levels of most cytokines are not 
correlated with cortisol levels in healthy, non-traumatized individuals as well as in 
trauma-exposed men with and without PTSD. An important issue connected with 
inflammatory status of trauma-exposed individuals with and without PTSD, which 
remains to be further explored, is that increased inflammation may be a 
pre-existing risk factor that results from personality traits or genetic factors. If 
reduced cortisol is not involved, or if patients with PTSD have normal circulating 
concentrations of cortisol (Meewisse et al., 2007), it is possible that enhanced 
glucocorticoid sensitivity of immune cells may be unable to overcome this 
inflammation. 
Corticosteroids are the most effective anti-inflammatory therapy for many 
chronic inflammatory diseases, such as asthma, rheumatoid arthritis and 
inflammatory bowel disease, but are relatively ineffective in other diseases, such as 
chronic obstructive pulmonary disease. Chronic inflammation involves the 
infiltration and activation of many inflammatory and immune cells, which release 
inflammatory mediators that interact and activate structural cells at the site of 
inflammation. Different inflammatory diseases involve different cells and 
mediators (Barnes et al., 1998), but common to all of them is increased expression 
of multiple inflammatory proteins, which are regulated at the level of gene 
transcription by proinflammatory transcription factors, such as NF-κB and AP-1. It 
is now believed that chromatin remodeling plays a critical role in the 
transcriptional control of inflammatory genes. Stimuli that switch these genes on 
act by changing the chromatin structure of the genes, whereas corticosteroids 




recruitment of histone deacetylase-2 (HDAC2) to the activated transcription 
complex (Barnes, 2006). 
Anti-inflammatory actions of glucocorticoids are typically mediated by pro-
inflammatory transcription factors, such as NF-κB and AP-1 (Adcock & Caramori, 
2001). Several models exist to explain the glucocorticoid-induced repression of 
AP-1 and NF-κB signaling. In the direct-interaction model, GR and AP-1 interact 
and prevent binding of each other to their response elements (Wargnier et al., 
1998). In the competition model, GR and AP-1 compete with one another for 
binding to their overlapping response elements, while in the co-activator 
competition model, GR competes with NF-κB and/or AP-1 for binding to cyclic 
AMP-responsive element-binding protein (CBP), which is present in the cell in 
limiting amounts (Kamei et al., 1996; Sheppard et al., 1998). Furthermore, the 
GR-mediated repression of trans-activation by the p65 subunit of NF-κB is 
increased in the presence of CBP, suggesting that CBP functions as an integrator of 
the NF-κB/GR cross-talk (McKay & Cidlowski, 2000). In the histone 
acetyltransferase (HAT) inhibition model, GR binding to CBP inhibits recruitment 
of CBP by DNA-bound p65, reducing the HAT activity of the complex (Adcock & 
Caramori, 2001). Yet another possibility is an up-regulation of the inhibitor of NF-
κB action (I-κB) in response to glucocorticoids (Deroo & Archer, 2001). However, 
recent results showing that dimerization-impaired GR DNA-binding domain is 
capable of DNA-binding (Adams et al., 2003) and up-regulation of GRE-dependent 
genes (Rogatsky et al., 2003) have shed some doubts on whether the anti-
inflammatory actions of glucocorticoids are indeed independent of DNA-binding. 
An important observation in the present study is that life-time PTSD subjects 
demonstrated the lowest level of analyzed cytokines compared to all other groups, 
thus particularly underlying the role of attenuated inflammatory response in th e 
recovery from PTSD. It is noteworthy that IFN-γ is the only cytokine that is 
decreased in the life-time PTSD patients, compared to healthy controls, whereas it 
was not changed in other two groups (current PTSD and trauma control). The 
decrease of IFN-γ in the life-time PTSD group could be a consequence of the most 




groups, since this cytokine acts as a potent inducer of IFN-γ production. Besides, 
this finding points to IFN-γ and IL-12p70 as the cytokines with possibly important 
roles in recovery from PTSD. 
Since net effects of inflammatory response are determined by the balance 
between proinflammatory and anti-inflammatory cytokines, we analyzed the level 
of anti-inflammatory cytokine IL-10. The level of IL-10 was decreased in the 
groups of current PTSD and life-time PTSD patients, compared to healthy controls, 
while trauma controls were not significantly different from healthy controls. This 
result, in the light of the observed decrement of proinflammatory cytokines TNF-α, 
IL-6, IL-12p70, IL-2 and IL-8 in the three groups of trauma-exposed subjects, 
makes a difference between patients with PTSD and trauma controls in the overall 
balance between pro- and anti-inflammatory cytokines. 
As yet, there is insufficient information to provide answers about the immune 
system contribution to PTSD vulnerability or progression. Additional research is 
needed, which hopefully will uncover physiologic mechanisms, thus providing 
opportunities for new pharmaceuticals or novel treatment approaches (Silverman 





1. Basal plasma cortisol level alterations are not associated with trauma 
exposure, current or life-time PTSD symptoms, resilience to PTSD, 
vulnerability to PTSD or with remission of the disorder. 
2. Hypersensitivity of HPA axis to cortisol might be a biological correlate of 
vulnerability to PTSD. 
3. Vulnerability to PTSD is characterized by increased level of GR expression in 
PBMCs. 
4. War trauma-exposure, symptoms of PTSD, vulnerability or resilience to PTSD 
and remission of the disorder are not associated with the changes in MR level 
or in MR/GR balance in PBMCs. 
5. The levels of expression of HSPs (Hsp90, Hsp70, Hsp72 and Hsp60) do not 
vary between current PTSD, life-time PTSD, trauma control and healthy 
control groups of subjects. 
6. MR level in peripheral lymphocytes is correlated with the levels of both 
Hsp90 and Hsp70, while the GR level is correlated only with that of Hsp90. 
7. Current PTSD is related to the strength of correlation between the levels of 
MR and Hsp70, while war trauma-exposure may improve correlation 
between the levels of GR and Hsp90 in peripheral lymphocytes. 
8. Subjects belonging to current PTSD, life-time PTSD, trauma control and 
healthy control groups do not differ in respect to blood plasma levels of 
Hsp60 and constitutive and inducible isoforms of Hsp70. Thus, the 
extracellular levels of these HSPs can not be related to war trauma-exposure, 
symptoms of PTSD, vulnerability or resilience to PTSD and remission of the 
disorder. 
9. Judging by the level of general inflammatory markers (CRP, erythrocytes 




current or life-time PTSD is similar to that of traumatized non-PTSD subjects and 
non-taumatized healthy controls. 
10. The highest levels of pro-inflammatory cytokines (TNF-α, IL-6, IL-12p70, IL-2, IL-8, 
IFN-γ, IL-5, IL-4) and anti-inflammatory cytokine (IL-10) were observed in the blood 
plasma from participants belonging to healthy control group in comparison to other 
study groups, implying that trauma-exposure and PTSD could rather be linked to 
immunosuppression than to enhanced inflammation. 
11. Cytokines such as TNF-α, IL-6, IL-12p70, IL-2 and IL-8 were present at significantly 
lower levels in the plasma from the three groups of trauma-exposed subjects 
(current PTSD, life-time PTSD and trauma controls) as compared to healthy controls, 
meaning that the level of these pro-inflammatory cytokines might be connected with 
trauma-exposure rather than with the presence of current or life-time PTSD 
symptoms. 
12. The levels of IFN-γ, IL-5, IL-4 and IL-10 were significantly lower in current PTSD and 
life-time PTSD groups than in trauma and healthy control groups, suggesting that 
the level of these cytokines could be related to vulnerability to PTSD rather than to 
trauma-exposure. 
13. In general, plasma cortisol level is not associated with the levels of the cytokines. 
The exceptions are IL-12p70 in the healthy control group, IL-4 and IL-5 in the 
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